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Abstract
In this thesis, I examined the effect of human papillomavirus (HPV) on the proinflammatory
IL-18 cytokine pathway in head and neck cancers. I investigated the expression and
methylation of genes associated with this pathway using The Cancer Genome Atlas (TCGA)
data. In HPV+ cancers, IL18, CASP1, and AIM2 were downregulated, while IL18BP was
upregulated compared to HPV- cancers and adjacent non-cancerous tissues, and IL18’s
promoter was significantly more methylated. I compared HPV+ and HPV- head and neck
cancer cell lines for expression of RNA and protein levels of IL-18 and IL-18BP by qPCR,
western blot, and ELISA. IL-18 mRNA and protein levels were lower in HPV+ cells, while
IL-18BP mRNA was higher. The E7 protein from most HPV types repressed an IL18 luciferase
reporter and this required conserved region 3 of HPV16. Repression of IL-18 mediated
inflammation may help HPV evade the immune system and contribute to chronic infection.
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Summary for Lay Audience
Human papillomaviruses (HPV) are an expanding cause of cancer in the global theater of
human disease and are responsible for ~5% of cancers world-wide. HPV is the root cause of
practically all cervical cancers, a large number of anogenital cancers, and at the focus of this
thesis, a rising number of head and neck cancers. These HPV+ cancers are biologically unique
when compared to their HPV- counterparts. They express the viral HPV cancer causing genes
early gene 6 (E6) and early gene 7 (E7) integrated into their own genome. These viral genes
encode proteins that disrupt our cell’s ability to control their replication, repress their ability to
die in response to cancerous growth, and signal the immune system that they are infected. This
allows HPV infected cells to divide uncontrollably and avoid the immune system. The
avoidance of the immune system is important to HPV’s ability to cause cancer, as the immune
system normally destroys cells within a state of uncontrolled replication. We identified and
began to study an additional way by which HPV avoids the immune system, through the
suppression of the interleukin-18 (IL-18) inflammatory pathway. IL-18 is an important
component of the immune system within our skin, and functions by activating immune cells
with anti-viral and anti-cancer properties. As HPV infects skin cells, avoiding the IL-18
proinflammatory response is an important barrier to surpass and may contribute to the ability
of this virus to establish and maintain infection. In this thesis, I explore the impact of HPV on
expression of IL-18, components of the protein complexes that activate it, and its suppressor
IL-18 binding protein (IL-18BP) in head and neck cancers. I found a consistent and targeted
downregulation of the IL-18 pathway, which I attributed to HPV E7. Suppression of this
inflammatory pathway has significant implications on the establishment and maintenance of
infection by HPV and could contribute to the ability of HPV to cause head and neck cancer.
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Prelude
In regard to viruses, wherever life can be found viruses can be found too. From the atmosphere
to the depths of the sea, viruses are as abundant as they are diverse and infect all kinds of life.
Structurally, viruses are bundled packages of either DNA or RNA, tightly packed within a
series of repeating and interlocking proteins called the viral capsid. This capsid too can be
enveloped within a host derived phospholipid membrane. Viruses are obligate intracellular
parasites. This means that they require the biochemical machinery of the cells they infect to
replicate themselves and transcribe their genetic material into mRNA and translate those into
proteins (Krupovic M., et al 2019). Due to their lack of endogenous metabolism and ability to
replicate themselves, it is a topic of debate whether viruses are actually living entities or just
bundled packages of genetic material (Wessner D. R. 2010).
Considering the state of the world in 2020 and the current global pandemic of the SARS-CoV2
Coronavirus, the importance of understanding and studying viruses has never been clearer.
Upon infection of a host, viruses can cause a variety of diseases and disorders by disrupting
biological homeostasis and activating or suppressing the immune system (Woolhouse M. et al
2012). This hijacking of host endogenous functions by viruses to promote replication and
infection can have a wide variety of negative effects, producing symptoms that may cause both
immediate and long-lasting harm (Speck S. H. and Ganem D. 2011). These symptoms
encompass a wide variety of illnesses, including excessive inflammation, the breakdown of
infected tissue, and the abnormal replication of host cells. A subset of viral infections can
induce oncogenesis in their infected hosts and are aptly named tumour viruses (Table 1.1).
According to the World Health Organization (WHO), roughly 12-20% of the global cancer
burden is derived from viral infections (Mersi E. A. et al 2015). This is typically attributed to
the virus’s ability to alter host gene function and protein expression. Specifically, in order to
create an environment ideal for viral infection and cellular replication, these viruses repress
host inflammation and anti-tumour genes, while promoting cellular proliferation. One such
example of these viruses is the Human Papilloma Virus (HPV). The focus of this thesis is to
identify and investigate interactions of HPV with its host cells that contribute to head and neck
cancer. Specifically, I am examining the effects of the HPV oncogenes on the IL-18 pathway,
and how this interaction contributes to the etiology of HPV-derived head and neck cancer.
xvii
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Chapter 1

1

HPV

1.1 Introduction to HPV
HPV is the etiological agent of what are colloquially known as warts or papillomas.
According to the Center for Disease Control (CDC), HPV is one of the most common
sexually transmitted diseases on earth. It is estimated that nearly 80% of sexually active
adults will contract this virus at some point within their lifetime (CDC, 2017). This is not
a new phenomenon however, as HPV and the subsequent cutaneous warts they can induce
have been recorded since the times of ancient Rome (Celcus A. C. 47AD). The etiological
agent of these warts had eluded researchers for centuries, being thought to have been
caused by anything from close contact with farm animals, to religious punishment for
masturbatory behaviors (Burns D. A. 1992). It was not until the experiments of Dr.
Giuseppe Ciuffo in 1907 that it was hypothesized to be an infectious agent, most likely a
virus, that was inducing these cutaneous lesions. He explored this theory experimentally
by taking the lysate of a wart that had been passed through a Berkfeld filter, a filter fine
enough to remove both bacterial and fungal pathogens and inoculating his own hand with
the lysate. Subsequently, at the site of inoculation warts developed within the following
weeks (Ciuffo G. 1907). The viral cause was later supported in the year 1949 where the
crystal structure of virus like particles were observed in processed wart tissue samples
(Strauss et al 1949). As time passed and these lesions were investigated and researched,
they were eventually designated as a group of viruses called the papova viruses, and this
was later changed to the papillomaviruses of Papillomaviridae (PV) family (Strauss et al
1949, Melnick J. L. 1962, Bravo I. C. and Félez-Sánchez M. 2015).
This research and identification of the PV viruses cumulated in one of the most important
scientific discoveries of the century within both the fields of virology and oncology. In
1983, Dr. Harald zur Hausen identified HPV-16 and 18 viral genomes within the genome
of carcinomas of cervical cancer patients, as well as cervical cell lines. He was able to
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Table 1.1: Currently described oncogenic tumour viruses associated with human
cancers
This table encompasses the viruses in which have been confirmed to cause human cancers.
Virally derived cancers account for approximately 12-20% of cancers worldwide through
the alteration of host endogenous gene expression and function.
Adapted from Brubaker J. American Society for Microbiology 2019
Virus Family
Hepatitis B
(HBV)

Hepatitis C
(HCV)

Epstein-Barr
Virus (EBV)

Merkel Cell
Polyomavirus
Kaposi’s
Sarcoma
Associated
Herpesviruses
(KSHV)
Human Adult Tcell Leukemia
Virus Type-1
(HTLV-1)
Human
Papilloma
Viruses (HPV)

Human Tumours
Hepatocellular carcinomas. The integration of HBV into the host
genome and an overexpression HBV surface antigen in the endoplasmic
reticulum causing hepatocellular damage through reactive oxygen
species (ROS) and decrease apoptosis initiated by p53, Fas, Tumor
Necrosis Factor (TNF) and Tissue Growth Factor Beta (TGF-B). The
hepatitis family of viruses cause roughly 5% of worldwide cancers
Hepatocellular carcinomas. Unlike HBV, HCV is unable to integrate
into hepatocytes genome. Instead they remain latent within hepatocytes
causing irreversible liver fibrosis, genetic, and epigenetic changes, of
anti-tumour genes like p53, PIKCA, and beta-catenin
Burkitt’s Lymphoma, Hodgkin’s Disease, nasopharyngeal carcinoma,
stomach adenocarcinoma. EBV dysregulates the expression of the myc
proto-oncogene causing alteration in cell cycle, apoptosis, and cellular
transformation. Causes roughly 1% of the world-wide cancer burden.
Merkel cell carcinoma. This is a skin cancer of neuroendocrine origin
associated with infection by this polyomavirus and is most commonly
found within sun-exposed individuals and the immunocompromised.
Kaposi’s sarcoma, primary effusion lymphomas, and multicentric
Castleman’s disease. This is the most common cancer in untreated HIV
patients. KSHV in immunocompromised patients results in
dysregulation of cell proliferation and metabolism in endothelial cells,
resulting in roughly 1% of the worldwide cancer burden.
T-cell leukemia. HTLV-1 is a retrovirus that infects T cells, and
infection leads to adult-T-cell leukemia in roughly 2-5% of infected
individuals.
Cervical/Anogenital/Head and Neck Squamous cell carcinomas.
Carcinomas of the infected mucosa through integration of oncogenic
viral genes into the host genome, dysregulating apoptosis through
degradation of p53 and the pRb family of cell cycle regulators. Causes
roughly 5% of the worldwide cancer burden.
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draw the connection between the virus and its ability to cause these abnormal growths of
epithelial cells into papillomas and the eventual development of cancer (zur Hausen H., et
al 1983). This groundbreaking research established that HPV infections are not only
medically significant, but that human viruses can induce oncogeneses in their host cells.
This earned Dr. zur Hausen the Nobel prize in medicine in 2008.
Following the revelation of HPV’s association with cervical cancer, the need for a
vaccination against this infection became of interest for the health of the general
population. This push for an effective and safe HPV vaccine eventually came to fruition in
2006, as a prophylactic vaccine entitled Gardasil became commercially available from
Merck & Co. pharmaceuticals. This vaccine is based on the major capsid protein of HPVs
viral protein shell, which can self-assemble into a virus-like particle capable of initiating
an adaptive immune response. This promotes the development of neutralizing antibodies,
allowing for the sequestration and removal of viral particles upon infectious exposure,
resulting in a lasting immunological response (Johnson A. L. 2007).

1.1.1

HPV Biology

HPV is a member of the Papillomaviridae family of viruses. These viruses are notorious
for their ability to cause both benign and malignant growths of epithelial cells across the
animal kingdom, with PV species infecting not only mammals, but birds, fish, and reptiles
as well (Van Doorslaer K et al. 2018). These viruses are highly species specific. As such,
HPV can only productively infect the epithelia of humans. As it currently stands, there are
well over 200 different HPV types.
HPV is a non-enveloped, double-stranded circular DNA tumour virus with a genome of
approximately 8000 nucleotides, with 8 described genes. These includes HPV early genes
E1, E2, E4, E5, E6, and E7, as well as late genes L1 and L2 (Figure 1.1). This genome is
packaged within an icosahedral capsid consisting of 72 protein pentamers consisting of
HPVs major and minor capsid proteins, L1 and L2 respectively (Figure 1.1). This results
in a 55nm diameter viral infectious particle (DiGiuseppe S. et al 2017). Despite sharing
these common traits across the many different types of HPV, these viruses are roughly
divided into five separate categories based on a variety of factors, including the tissues they
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infect, the type of lesion they produce, their ability to immortalize cells, and histological
presentation. These categories of HPVs include the Alpha-viruses, Beta-viruses, Gammaviruses, Mu-viruses, and Nu-viruses (de Villers et al 2004). The topic of this thesis will
encompass the activities and oncogenic properties of the HPV Alpha-viruses.
The alpha-HPVs infect the mucosal tissues of humans and induce abnormal, continuous
replication of epithelial cells (Gheit T. 2019). The alpha-HPVs are of interest and scientific
importance as they contain what are considered the high-risk and low risk HPVs. The highrisk HPVs infect only the mucosal epithelia of the cervix, the head and neck, and the
anogenital track and initially present as a papilloma of the mucosa. These papilloma start
out as benign lesions, but should the host fail to clear the viral infection, the lesion may
progress to malignancy (Shanmugasundaram S. and You J. 2017). The currently identified
high-risk HPVs are HPV-16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and
82 (Munoz N. et al 2003, Burd E. M. 2003, Sunderström et al 2015). The low risk alphaHPVs are mucosal HPVs that typically cause benign lesions and warts, although these
infrequently progress to carcinomas. The low risk alpha-HPVs encompass HPV 6, 11, 42,
43, 70, and 90 (Burd E. M. 2003, Sunderström et al 2015)

1.1.2

HPV Viral Entry

The infectious cycle of HPV is a complex dance of gene expression, where the translation
of their 8 genes is carefully orchestrated in a manner that allows the virus to remain
undetected, yet still accomplish its goals of infection and progeny production. This process
begins when the virus is introduced to the epithelia through contact with virus present in
shed infected epithelia. Here, the virus will descend through the stratified epithelia infect
the lowest defined layer, the basal epithelium. The virus passes through these upper
cornified layers of the epithelium through micro abrasions, which are small cuts and tears
within both mucosal and cutaneous epithelium that occur through the regular wear and tear
of daily life (Figure 1.2)(Stanley M. et al 2010). Once within the basal layer of the
epithelium, HPV virions now enter the cell. The L1 virion protein binds membrane-bound
cellular receptors the heparin sulphate proteoglycans (Schiller J. T. et al 2010, Raff A. B.
et al 2013). This induces the endocytosis of the virion.
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Figure 1.1: The genomic organization of HPV-16’s genes
HPV-16 has a roughly 8000bp long double-stranded DNA genome which contains 8 genes.
The genome is divided into three regions. The early region, where the E1-E7 genes reside,
are expressed during the initial infection. The late region, where the capsid proteins L1 and
L2 reside, are only expressed in terminally differentiated keratinocytes. The third region is
the regulatory region, called the long control region (LCR), which contains the viral origin
of replication and transcriptional control signals for early and late gene expression.
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Upon maturation of the endosome and transport via the trans-Golgi network, the viral
particle arrives at the nucleus through the endoplasmic reticulum. The L2 protein facilitates
the disassembly of the viral capsid and the release of the viral DNA from the endosome to
the nucleus upon cellular replication and disassembly of the nuclear membrane. The HPV
genome is subsequently maintained extra-chromosomally, as an episome (DiGiussipe S. et
al 2014/2016, Aydin I. et al 2014).

1.1.3

E1 and E2

Once the virus has established itself in the nucleus, its next requirement is to replicate its
own genome and to begin expressing the viral early genes. The first viral proteins expressed
upon infection are the early genes E1 and E2, which direct and facilitate the replication and
expression of the rest of HPVs genes. E1 is the only protein within the HPV genome with
a conserved enzymatic activity and its main function is to initiate and regulate the
replication of the HPV genome (Bream G. L. et al 1993). E1 initially binds to the HPVs
genome origin of replication within the LCR, and acts as an ATPase, as well as a DNA
helicase. Once bound to the viral DNA, E1 forms a hexamer and initiates elongation of
viral DNA using the cellular DNA replication apparatus. This binding efficiency is weak,
however, and is amplified with the assistance of E2 (Castro-Muñoz L. J. et al 2019).
E2 is a regulatory protein that modulates the expression and replication of HPVs genes. E2
is both a transcriptional repressor, or a transcriptional activator, depending on where in the
genome it associates and what it is bound to (Spalholz B. A. et al 1985). The E1-DNA
complex has a weak affinity to the origin of replication on the HPV genome, an affinity
that is greatly increased when E2 is present. This protein complex acts to regulate the
recruitment of DNA replication machinery as well as translational machinery. This E1-E2
complex allows for a controlled replication of not only the HPV genome, but also a
controlled, restrained expression of HPVs oncogenes depending on the differentiation
status of the host cell (Hedge R. S. 2002). Typically, within an HPV infection, there are
fewer than 100 copies of the genome and low expression of HPVs other early proteins, E6
and E7, within the basal layer of the epithelium. This repression can be attributed to the
inhibitory effects of E2 (Maglennon G. A. et al. 2012). Despite the low level of
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Figure 1.2: The lifecycle of HPV
The HPV virion enters the host through micro-abrasions to infect the cells comprising the
basal layer of the epithelium. Here, the viral genome is maintained at a low frequency with
low expression of viral early genes. The basal cells then replicate, leaving one infected
daughter cell in the basal layer, as one infected daughter cell rises through the epithelium.
Typically, healthy cells differentiate and stop replicating as they move upwards through
the skin. These differentiated cells continue to replicate through a dysregulation of the cell
cycle mediated by the viral early proteins. As the cells rise further through the epithelium
layer, the late genes begin to be expressed coincident with terminal differentiation and the
viral genome is amplified. Here at the cornified layer of the epithelium, dead, virus
containing cells are shed into the environment continuing the cycle of viral dissemination
and infection. (Figure adapted from C. A. Moody and L. A. Laimins 2010)
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expression of its early genes, HPV is able to replicate its genome using both virus-derived
proteins and host-derived proteins, and is able to maintain a low antigenic presence within
the basal layer of the epithelium that helps evade the immune system, typically for months
or even years (Peh W. L. et al 2002).

1.1.4

E4 and E5

Two of HPVs least understood proteins, E4 and E5 are expressed during the differentiation
and replication of keratinocytes. HPV E4 is synthesized as a fusion protein with a portion
of E1, represented as E1^E4, as a result of RNA splicing, and sequence overlap with the
open reading frame (ORF) of E1 (Wang et al 2011). Despite being in the series of early
proteins it is suspected that the function of E4 falls within the later stages of viral
propagation as it is nearly undetectable in early viral infection (Doorbar et al 2013). While
its function is currently undescribed, it is suspected to function as a component of viral
release through the binding of keratin (Brown et al 2006).
HPV E5 has been gaining interest in the scientific community in recent years. While E5’s
functional properties are yet to be fully understood, it is now considered one of HPVs
oncogenes. Although its function is not necessary for HPV infection and oncogenesis, E5
has been shown to augment the transformative properties of E6 and E7 (Maufort J. P. et al
2010). E5 expression delays differentiation of the infected epithelial cell, assisting in the
maintenance of cell cycle progression (Muller M. et al 2015). E5 lacks any currently
described enzymatic activity, and it accumulates within the Golgi apparatus, the
endoplasmic reticulum, and the plasma membrane. E5 appears to be a transmembrane
protein and contains three close proximity hydrophobic regions with ɑ-helical structures
similar to other transmembrane proteins (Conrad M. et al 1993, Krawczyk E. et al 2011).
Through its association with these membranes, E5 is suspected to function as a viroporin.
It functions by promoting cell cycle progression through interaction with the epidermal
growth factor receptors pathway at the membrane and through blocking acidification of the
endocytic vacuole (Pim D. et al 1992, Schrevel M. et al 2011).
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1.1.5

HPV Transforming Protein E6

Despite there being currently three described HPV oncogenes, only two of them are
consistently retained within HPV induced cancers (Münger K. et al 2004). These proteins
are HPVs transforming E6 and the E7 oncoproteins. E6 protein is roughly 150 amino acids
(aa) long, containing two zinc binding domains within its structure. These domains are
crucial for HPVs survival and ability to transform cells (Martinez-Zapien D. et al 2016).
This is due to its ability to inhibit pro-apoptotic and anti-tumour protein, p53 (Pol A. B. V.
and Klingelhutz A. J. 2013). The function of p53 is one of the largest hurdles any tumour
virus or cancer has to overcome, due to its ability to induce apoptosis within cells where
there is irreparable DNA damage/mutation, oncogene expression, cellular stress like
hypoxia found within tumour environments, and most importantly, inappropriate DNA and
cellular replication (Zilfou J. T. and Lowe S. W. 2009).
To avoid the function of this pro-apoptosis gene, E6 binds and degrades p53. It does this
through associating with and co-opting the function of the cellular E6-associated protein
(E6-AP). E6 and E6-AP form a heterodimer, which binds p53 to form a heterotrimer
(Scheffner M. et al 1993). E6 and E6-AP function as a ubiquitin-protein ligase and they
ubiquitinate p53, tagging it for proteolytic degradation through the proteasome (Figure 1.3)
(Garnett T. O. and Duerksen-Hughes 2006). E6 has also been reported to prevent p53
independent apoptosis through the binding and inhibition of several other proapoptotic
proteins, including Bak, c-Myc, and TNF receptor 1 (Thomas M. and Banks L. 1998,
Gross-Mesilaty S. et al 1998, Filippova M. et al 2002).

1.1.6

The HPV E7 Oncogene

E7 is a roughly 100aa long protein and is a highly conserved cancer-causing gene across
the different types of HPV. As the function of E7 is predominantly nuclear, it is found
mostly in the nucleus of infected cells (Smotkin D. and Wettstein F. O. 1987). The E7
100aa are divided into a series of conserved regions (CR), CR1, CR2, and CR3. CR1 of E7
spans the first 15aa of the protein, CR2 encompasses residues 16-38, and CR3 has the lion’s
share domains with significant sequence homology to the human adenovirus (hAdV) early
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Figure 1.3: The activity of HPV-16 E6
The activity of E6 as represented through a stepwise diagram of the assembly of the
ubiquitin ligase complex. E6 initially binds the E6-AP resulting in a heterodimer that
complexes with p53. Ubiquitin is then ligated to p53, marking it for proteolytic destruction
by the proteasome.
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protein 1A (E1A) (Phelps W. C. et al 1998). E7 CR2 contains a LxCxE motif (where x
represents any amino acid) which is responsible for E7s high affinity interaction with the
retinoblastoma family of tumour suppressors (pRb, p107 and p130) (Barbosa M. S. et al
1990, Münger K. et al 1989). E7s carboxyl terminal CR3 contains a zinc-binding domain,
comprised of two pairs of cysteines separated by roughly 30aa. These two domains are
essential for protein stability and function and have been implicated in E7s ability to
regulate transcription (Todorovic B. et al 2011, Songcock W. K. et al 2017).
E7 is utilized to keep the cells within a state of constant cell cycling through the
dysregulation of the host cell cycle G1 checkpoints. E7 does this through the exploitation
of the E2F transcription factors and inhibition of their negative regulators pRb, p107 and
p130 (Chan Y. K. and Gack M. U. 2016). The pRb family of proteins function as negative
regulatory proteins that sequester the E2F transcription factors, preventing them from
inducing transcription of their target genes. E2F transcription factors are the regulators of
expression for genes involved in controlling cell cycle progression from the G1 phase of
cellular growth to the S-phase of DNA replication (Johnson D. G. and Schneider-Broussard
R. 1998). This is where the synergistic effects of E6 are important, as the dysregulation of
the cell cycle is one signal that potently activates p53. High-risk HPV are especially
efficient in this deregulation of the pRb family of proteins by destabilization via
ubiquitination and subsequent proteasome degradation instead of just binding and
inhibiting pRb through steric hindrance (Figure 1.4) (Todorovic B. et al 2012, Oh K. J. et
al 2010).
E7 also has pro-HPV replication activity within these epithelial cells through altering the
methylation of gene promoters. E7 CR3 has been shown to facilitate the binding and
activation of host cell DNA methyltransferase 1 (DMNT1) (Burgers W. A. et al 2007,
Songcock W. K. et al 2017). While the exact mechanism in which binding effects gene
methylation is poorly understood, it has been implicated in the altered methylation of
several gene promoters that interfere with the function and infection of HPV. These include
genes encoding cell cycle regulators and proinflammatory cytokines. For example,
knockdown of E7 using siRNA in HPV positive cells significantly reduced promoter
methylation of Cyclin A1’s promoter (CCNA1), an important regulator of the G1-S-phase
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cell cycle checkpoint (Chalerpet K. et al. 2015). The proinflammatory chemokine
CXCL14, which promotes immune cell migration (Cicchini L. et al 2016), and Human
Leukocyte Antigen E (HLA-E/MHC-I) a regulator of NK cell and CD8+ cell interaction
(Cicchini L. et al 2017) have both been shown to have hypermethylated promoters in HPV
derived cervical cancers.

1.1.7

L1 and L2

Once the host cell reaches the upper layers of the epithelium, terminal differentiation has
occurred, and this initiates the production of HPV late proteins. These consist of the L1
and L2. The major capsid protein L1, once translated, spontaneously self-assembles
without the need of chaperone or scaffold proteins into a facsimile of the final virion
(Schiller and Lowy 2012). The purification of recombinant L1 protein is the basis for
current HPV vaccines, as even in vitro the purified L1 protein can self-assemble into viruslike particles (VLP) (Buck C. B. et al. 2013). The minor capsid protein L2, however, is
vital to produce mature virions. L2 associates with HPVs genome and the L1 major capsid
proteins, facilitating encapsulation of the viral genome. These two proteins working in
tandem are required for the final production of mature virions, ready to be released and
infect anew (Wang J. W., Roden R. B. S. 2013).
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Figure 1.4: The activity of HPV-16 E7 on the cell cycle
E7 functions through binding the pRb family of proteins, blocking them from binding and
inhibiting their target the E2F transcription factors. In high-risk HPV like HPV-16, this
repression is further mediated through the proteolytic destruction of pRb through the
proteasome.
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1.2

HPV and Cancer

The transformation of HPV infected cells is not the typical end result of infection. In most
cases, HPV infections persist for a few months before successful resolution of the infection
by the immune system of the host. These infections may be asymptomatic or present with
the development of papilloma and warts. HPV-derived cancers are far more infrequent, and
are the product of long-term, chronic infections by high-risk HPVs in the mucosa, either
from chronic reinfection of the tissue or from the host’s inability to clear HPV infection
(Shanmugasundaram S. and You J. 2017). These long-term infections may also be
asymptomatic, resulting in an insidious infection with few warning signs to the cancer that
may lie in the future. Chronic infections by high-risk HPV make up approximately 10-20%
of cases of HPV infection (Moreno-Acosta P. et al 2020). There are several alleles within
the human body that are associated with enhanced susceptibility to these chronic infections,
like the phenotype of the infected HLA series of proteins, being of the male sex, and patient
ethnicity (Bernal-Silva S. et al 2013, Wank R. and Thomssen C. 1991).
These chronic infections can result in a tumultuous downwards spiral of the HPV infected
cells, where the continuous expression of viral oncogenes wreak havoc on the host cell. As
the cells are forced to continuously replicate, the host genome will begin to acquire DNA
damage and accumulate potentially oncogenic mutations. As HPV E6 inhibits apoptosis in
response to the DNA damage response, the host cell is unable to die in response to the
accumulation of mutation and damage (Garnett T. O. et al. 2006). As mutations begin to
accumulate in the host cell’s genome, genetically unstable regions of host DNA, called
common fragile sites, will reach their breaking point and undergo double-stranded DNA
breaks (McBride A. A. 2017). It is in these common fragile sites that the HPV viral
oncogenes can be found to be integrated into the host genome, a hallmark of HPV derived
cancer. With expression of HPVs oncogenes from integrated viral genomes (Jeon S. and
Lambert P. F. 1995), and the loss of E2 expression and its repressive effects on E6 and E7
expression (Collins S. I. et al 2009), these oncogenes are expressed at much higher levels,
driving malignant progression.
In the past decades, HPV has been rising in prevalence as an etiological agent of a variety
of cancers. It is currently estimated that HPV is responsible for roughly 5% of human
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cancers world-wide and is particularly impactful on populations within developing
countries. HPV is perhaps best known for its role in cervical cancers. It has been identified
to be nearly universally present within cervical cancers, with the high-risk subtypes HPV16 and HPV-18 making up to 70% of these cases. According to the Global Cancer
Observatory database, a summation of cancer data from 185 countries, there were
approximately 600,000 cases of HPV derived cervical cancers and 311,000 deaths annually
(Arbyn M., et al 2019). It is not only the cervix where HPV sows the seeds of cancer. HPV
is also the etiological agent of a large subset of anogenital cancers, as well as a growing
subset of cancers of the head and neck (Bansal A. et al 2016).

1.2.1

Head and Neck Squamous Cell Carcinomas (HNSCC)

Head and neck squamous cell carcinomas (HNSCC) are cancers that arise within the
epithelium within the mucosa of the mouth and throat. They can be divided into 4 subsites,
comprised of the oral cavity, hypopharynx, oropharynx, and the larynx (Boyle P and Levin
B. 2008, Jemal A. et al 2007). Each year there are roughly 600,000 cancer diagnoses of the
head and neck, and nearly 300,000 corresponding deaths, making it the sixth most
prominent causes of cancer world-wide, and one of the deadliest (Alsahafi E. et al 2019).
The prognosis of head and neck cancers is typically quite poor, with a five-year survival
rate of 40-50% depending on stage of disease, HPV status, and biological subsite (Leemans
C. R. et al 2011). Cancers of the head and neck are a heterogenous disease, and can be
divided into two biochemically distinct subclasses, HPV+ tumours and HPV- tumours.
Typically, cancers of the head and neck are derived from habitually consumed carcinogens
like tobacco and excessive drinking, environmental factors like air quality and workplace
gaseous hazards, and infection with high-risk HPVs (Shaw R. and Beasley N. 2016).
Treatment of cancers of the head and neck ranges from surgical removal, radiation therapy,
and/or chemotherapy. Due to the location of these cancers and the current state of medical
intervention, there is a sharp reduction in the quality of life of head and neck cancer
patients, as treatment can cause discomfort, disfigurement, and loss of function of
important components of their head and throat. This ranges from cosmetic damage to the
face, to the inhibition of speech and inability to swallow due to damage to the jaw and
larynx (Dropkin M. 1989). Thankfully, due to awareness campaigns and initiatives to
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reduce smoking, the incidence of HPV- HNSCC has been on the decline (Fakhry C. et al
2018).
This decrease has not, however, caused an overall decline of all cancers of the head and
neck, as HPV derived HNSCCs have been rising at epidemic rates. As the etiological agent
of these cancers begins to change, so too has the demographics of the patients. Patients
with HPV+ cancers tend to be younger and healthier, with an overall better prognosis when
compared to traditional HPV- HNSCC patients who are older with mutagen derived
cancers. In the work of Dr. Adam Burr, he has shown that patient survival with HPV+ head
and neck cancers has a median time of 23.8 months, nearly twice the median amount of
months as those with HPV- cancers at 11.1 months (Ang K. K. et al 2010, Burr A. R., et
al 2018). While the prognosis is still quite poor, patients with HPV-associated head and
neck cancer respond better to radiotherapy and have improved survival (Maxwell J. H. et
al 2016). While the reasoning behind this improved prognosis and survival is still being
investigated, it is understood that these differences in survival are most likely attributed to
the younger age of the HPV+ patients, improved health in non-smoking HPV+ cancers, as
well as the unique tumour microenvironment associated with HPV+ cancer.

1.2.2

The Cancer Genome Atlas (TCGA)

One of the most powerful research tools in the sphere of bioinformatics are databases. One
such database that has been the foundation for countless cancer research projects is the
Cancer Genome Atlas (TCGA). This online database represents a massive collection of
molecular and clinical data acquired from cancer patient samples all over the world. Cancer
patients consented to the use of their tumour and treatment data for scientific research
allowing the National Cancer Institute (NCI) and National Human Genome Research
Institute (NHGRI) to coalesce the data all within a single database. This resulted in nearly
2.5 petabytes of data, encompassing the information of over 11,000 cancer patients with
33 different types of cancer, all within a single source. This includes genomic, epigenetic,
proteomic, transcriptomic, survival data, and clinical data. Importantly, with respect to the
analyses undertaken in this thesis, the TCGA includes DNA methylation data and
quantitative RNA-seq data (Li B. and Dewey C. N. 2011).
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Within this database, there is a subsection of data encompassing a large cohort of head and
neck cancer patients. In addition to the analysis of tumour samples, in some cases the
TCGA repeated the same analysis they conducted on tumours on non-cancerous adjacent
tissues, which serves as a useful control. In addition to this, the HPV status of these head
and neck tumours is reported within the database. This results in three distinct subsections
of head and neck samples, HPV+, HPV-, and normal adjacent non-cancerous tissues. Since
the data was generated via a uniform pipeline and normalized, it allows for quantitative
comparison between the three tissue types.

1.3

The Epithelium

To look at the immunogenic environment that HPV must overcome to establish and
maintain an infection and identify potential immunological components that can contribute
to cancer etiology, I will briefly describe the immune environment of the skin. As described
above, high-risk HPV infects keratinocytes of the mucosal epithelia. The epithelium is an
important physical and chemical barrier to microbes, including both commensal and
pathogenic, and has a robust immunogenic landscape (Duckney P. et al 2013). The
epithelium is the largest organ within the human body, and typically our first line of defense
against pathogens and inflammatory agents in our environment. Due to its status as the first
line of defense, our epithelium must be able to both respond quickly to immunological
insult through the innate immune system and appropriately activate the adaptive immune
system.
The epithelium functions as a physiological barrier to infection, a source of chemical
defense, and a place for immune cells to reside. In addition to the integrity of the mucosal
epithelium itself, an additional barrier to entry is a difficult to traverse layer of mucus,
which is filled with a variety of antimicrobial peptides and molecules, including lysozymes,
peroxidases, compliment components, defensins, and neutralizing antibodies like
immunoglobulin A (Schleimer R. P. et al 2007). Epithelial cells themselves recognize
pathogen-associated molecular patterns (PAMPs), which trigger innate immune responses,
such as upregulation of inflammatory mediators like type I interferons, and enhanced
antigen presentation in the context of Major Histocompatibility Complex Class I (MHC-I)
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(Hobbs C. G. L. et al 2006). An important cellular mediator of innate immune system
involved in barrier maintenance are Natural Killer cells (NK cells). Upon activation, NK
cells have anti-bacterial, anti-viral, and anti-tumour effects vital to the maintenance of
epithelial health through the secretion of interferon gamma (IFN-γ) and killing of
bacterial/virally infected cells (Fuchs A. and Colonna M. 2011).
The adaptive immune system is a potent and highly precise division of the immune system
and is pathogen specific. In response to inflammatory stimuli within the epithelium, the
recruitment of adaptive immune cells is mediated through the secretion of proinflammatory
cytokines and chemokines to induce T-cell differentiation and recruitment of CD4+ helper
T-cells (Th1 cells) and cognate cytotoxic CD8+ T-cells. In the epithelium, these cells are
vital for MHC-I recognition and the clearance of intracellular pathogens (Sinigaglia F. and
D’Ambrosio D. 2000). One cytokine of particular importance in epithelial barrier function,
which spans both the activation of the innate and adaptive immune systems in response to
viral infection, is Interleukin-18 (IL-18).

1.3.1

An Introduction to IL-18

IL-18 is an interferon inducing factor. It is constitutively produced by epithelial cells and
macrophages (Pirhonen et al 1999, Sugawara S. et al. 2001). IL-18 is a member of the IL1 superfamily of cytokines. This family of proinflammatory cytokines include the prototypical IL-1, as well as IL-18, IL-33, and recently IL-36 and IL-37 (Dinarello C. et al.
2010). These cytokines are all related through their biological origin, the structure of their
receptor, and the pathways they activate (Dinarello C. 2009). IL-18, similarly to IL-1,
requires cleavage from its initial pro-form to be rendered biologically active, most
commonly through the activity of the protease caspase-1.
Once IL-18 is activated, it is then subsequently secreted to initiate a proinflammatory
response from several types of immune cells. The method in which IL-18 is secreted is a
topic in which is poorly understood, as the protein lacks a secretory signal sequence
(Gardella S. et al 2000). It is currently understood that the secretion of IL-18 is increased
through the expression of vascular endothelial cell growth factor-D (VEGF-D). As VEGFD contains a metalloprotease domain, knockdown of the ADAM33 metallopeptidase was
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shown to inhibit the secretion of IL-18, indicating importance in the secretion process (Kim
K. E. et al 2009, Kim K. E. 2007)
Upon secretion, IL-18 activity is suppressed through sequestration by the soluble IL-18
binding protein (IL-18BP). The balance between IL-18 and IL-18BP determines biological
response. Once sufficient IL-18 has been secreted to overcome repression by IL-18BP
sequestration, it binds to receptors on both innate and adaptive immune cells, including NK
cells and T-helper cells respectively (Tomingaga K. et al 2000). IL-18 stimulates the
production of interferon gamma (IFN-γ) and immune cell activation, resulting in a swift
and powerful inflammatory response with a wide range of antiviral, antibacterial, and antitumour effects (Okumara et al 1998).

1.3.2

IL-18 Activation Through the Inflammasome

As IL-18 is constitutively produced within epithelial cells, the means of activation and
sequestration are the main methods of modulating its activity. IL-18 is initially produced
as an intracellular 24kDa pro-IL-18 protein, which is biologically inert (Mejias N. H. et al
2018). Pro-IL-18 is rendered biologically active through cleavage by caspase-1, which is
itself activated by the activity of one of several different types of inflammasomes.
Inflammasomes are multiprotein complexes that are constructed of either the NOD-like
receptor proteins (NLRPs) or the HIN-200 absent in melanoma protein 2 (AIM2) (Walle
L. V. and Lamkanfi M. 2011)
The NRLP inflammasomes are a complex of several proteins with NLRP1, NLRP3, and
NLRC4 being vital for its activity, with the NLRP3 inflammasome being directly
responsible for caspase-1 activation (Kanneganti T. D. et al 2006). In addition to its
function as a mediator of apoptosis and pyropotosis, it is also a potent activator of the
immune system in response to PAMPs and danger associated molecular patterns (DAMP).
PAMPs, as their name suggests, are foreign biological materials that cells can recognize
due to their exogenous nature and origin, like the lipopolysaccharide components of the
bacterial cell wall, viral DNA within the cytoplasm, double stranded RNA and viral
5’triphosphate RNA (Thompson M. R. et al 2011). These PAMPS are recognized through
either cytoplasmic or membrane-bound pattern recognition receptors (PRR). Upon the
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activation and priming of PRRs in response to PAMPS, NLRP3 transcription is
upregulated, transcribed, and assembled (Latz E. et al 2013). This also occurs as a response
to cellular stressors indicative of either tissue or DNA damage (Kelley N., et al 2019). The
inflammasome then mediates inflammation through the cleavage of several biological
mediators of inflammation, including the activation of caspase-1 (Cerreti D. P. et al 1992).
AIM2 is specifically important in regards to the activation of the immune system upon
infection with dsDNA viruses like HPV (Riva G. et al 2019). AIM2 is a PRR with a HIN
domain that senses the presence of dsDNA in the cytoplasm. Normally, in regular somatic,
non-dividing cellular environments, host DNA is sequestered within the nucleus. Thus,
surveillance and detection of cytoplasmic DNA is indicative of viral infection or severe
nuclear damage (Man S. M. et al 2015). Unlike other PRRs, which mediate the
transcription of NLRP inflammasome constituents, AIM2 binds dsDNA through their HIN
domain and subsequently binds with an adaptor protein ASC using their respective PYD
protein domains (Hara H. et al 2013). These ASCs contain a caspase recruitment domain
(CARD) that recruits pro-caspase-1. Using these protein structures as a scaffold, this
AIM2-ASC-Caspase-1 complex triggers the cleavage and activation of Caspase-1,
developing a catalytically active inflammasome protein complex (Wang B. and Yin Q.
2017).
Caspase-1, previously known as interleukin-1β converting enzyme (ICE), is a member of
intracellular cysteine proteases, which are able to cleave a narrow range of proteins in
response to its own activation (Nicholson D. W. 1999). As mentioned above, Caspase-1 is
initially translated as procaspase-1 and activated through its association with large
macromolecule scaffolds within the inflammasome through CARD-CARD (caspase
recruitment domains) and PYD-PYD (pyrin domain) protein interaction. After activation,
Caspase-1 subsequently cleaves and activates pro-IL-1β and pro-IL-18, to produce the
biologically active cytokine. (Franchi L. et al 2009).

1.3.3

IL-18 Binding Protein

Before secreted IL-18 can reach its receptor, it must overcome sequestration by IL-18
Binding Protein (IL-18BP). This secreted protein has an exceptionally high affinity for
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biologically active IL-18, binding it such that IL-18 is unable to interact with its receptor
(Kim S. H. et al 2000). IL-18BP is considered a decoy receptor and IL-18 becomes
biologically inert when sequestered by IL-18BP (Novick D. et al 1999).
IL-18BP, like IL-18, is also constitutively produced and secreted. In healthy humans
without inflammatory stimulus, IL-18BP is found at a nearly 20-fold higher concentration
in human serum compared to active IL-18 (Novick D. et al 2001). This is an important
method for keeping Th1-mediated inflammation in check, as even low levels of IL-18
activation have been associated with autoimmune and inflammatory disorders. Thus, the
constitutive production of IL-18BP surpassing that of IL-18 is important for maintaining
this low inflammatory level in homeostasis in the skin (Novick D. et al 2009, 2011).
IL-18BP is also important for terminating the IL-18 inflammatory response post-activation.
Indeed, IL-18-mediated inflammation needs to be silenced after triggering the desired
response, otherwise this risks excessive and damaging inflammation (Hurgin V. et al
2002). IL-18BP transcription and production is significantly increased in response to IFNγ in non-leukocyte cells, including epithelial cells. As IFN-γ is the key resulting product of
IL-18-mediated activation of NK and T-cells, the activation of IL-18BP expression spells
the end of the IL-18 inflammatory response (Mühl H. et al 2000). This essentially creates
a negative feedback loop, where IL-18’s suppressor is produced in response to IL-18
activation, allowing IL-18 to have a potent and fast stimulus of inflammation that is short
in duration.

1.3.4

IL-18 Activity

Once IL-18 has been activated, it is then subsequently secreted from the inflammasome
reactive epithelial cells in the skin. IL-18 then interacts with several different immune cells
through the IL-18 receptor (IL-18R). The IL-18R is a heterodimer of two membrane bound
proteins, IL-18Rɑ and β. They share similar homology to the IL-1β receptor, but the IL18R recognizes a molecular pattern within the second domain of IL-18 that is unique to the
cytokine (Tsutsumi N. et al 2014). This initiates the intracellular signaling through the
MyD88 pathway, eventually resulting in the activation of Nuclear Factor ĸB (NFκB) and
the mitogen-activated pathways of protein kinases (Weinstock J. V. et al 2003). NFκB is
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Figure 1.5: A summation of the IL-18 mediated proinflammatory pathway
In the presence of foreign PAMPs or endogenous DAMPs, membrane bound and
intracellular PRRs recognize their cognate molecular patterns. Upon recognition, the
stimulation of specific transcription factors induces the expression and subsequent
formation of the protein mega-complex called the NLRP3 inflammasome, or the AIM2
PRR directly binds to its associated proteins to form the AIM2 inflammasome. The
inflammasomes provide the scaffolding for the cleavage of pro-Caspase-1 into its active
form. Caspase-1 in turn cleaves pro-IL-18 into its active form in preparation for secretion.
Upon secretion, IL-18 must overcome the inhibitory threshold of IL-18BP, which serves
as a decoy receptor, to achieve a concentration sufficient for the activation of NK cells and
Th1 cells. Upon stimulation of the IL-18R, the NFκB transcription factors induce the
production and release of IFN-γ, which contributes to subsequent anti-viral functions.
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a transcription factor that regulates the expression of genes in response to an inflammatory
stimulus. In NK and T-cells, NFκB activation induces the production of several
proinflammatory cytokines, and primarily among these is IFN-γ (Pfeffer L. M. 2011). IL18 has the distinctive ability to activate components of both the innate and adaptive
immune system. Specifically, IL-18’s activity is costimulatory with IL-12 in the activation
and development of Th1 cells, NK cells, and B-cells (Harandi A. M. et al 2001). This is
largely due to IL-12’s ability to upregulate the production and presentation of the IL-18R
on these target immune cells. This enhances their sensitivity to the signaling of active IL18, assisting in the strong and swift induction of INF-γ (Yoshimoto T. et al 1998, Nakanishi
K. 2018).

1.3.5

IL18 and Disease

As previously mentioned, IL-18 has a complex relationship with a variety of diseases,
including autoimmune diseases, viral infection, and cancer. IL-18 has been implicated as a
marker for several inflammatory diseases, including systemic lupus erythematosus and
Wegener’s granulomatosis. In these diseases, the basal level of active IL-18 in the serum
of patients is high enough to overcome the barrier of IL-18BP inhibition, resulting in a
constitutive low level of inflammation dangerous to the circulatory system (Novick D. et
al 2009, Novick D. et al 2011).
IL-18 has also been proven to be an important cytokine for inhibiting viruses that infect
the epithelium. Indeed, several viruses that specifically infect the epithelium encode their
own homolog of IL-18BP in an effort to neutralize the IL-18-mediated inflammatory
response and the recruitment of cytotoxic T cells and NK cells. These viruses include
Molluscum contagiosum, a common infection of the skin (Xiang Y. et al 2001), as well as
one of the most devastating family of epithelial viruses known to man, the variola viruses,
including the smallpox virus (Xiang Y et al 2007). HPV, another epithelial tropic virus,
does not encode a homolog for IL-18BP, but instead upregulates the expression of host cell
encoded IL-18BP. In a paper by the MacDonald laboratory of Leeds University,
keratinocytes expressing HPV E6 and E7 displayed a pronounced increase in IL-18BP
production and secretion as a means of IL-18 sequestration. This paper directly identified

24

the suppression of IL-18-mediated inflammation as a new immune evasion mechanism of
HPV (Richards K. H. et al 2014).
Cancer also exhibits sensitivity to IL-18-mediated inflammation. In many cases, cancers
alter the activity of the cytokine by increasing the expression of IL-18BP and/or decreasing
the expression of IL-18. For example, IL-18BP has been found at elevated levels within
human ovarian epithelial cancers and has been hypothesized to represent an
immunotherapeutic target. (Carbotti G. et al. 2013). IL-18 has been suggested to exert its
anti-tumour effects through the activation of NK cells and cytotoxic T cells. These two
immune cell types have potent anti-tumour activity through the recognition and clearance
of cells showing signs of stress or uncontrolled replication. The activation of these cells is
important in the modulation of cancer treatment and destruction of precancerous cells, as
well as in cancer immunotherapy (Hu W. et al 2019, Farhood B. et al 2018). However, IL18’s relationship with cancer is significantly more complicated. The expression of IL-18
at high concentrations in cancer over a longer period was significantly correlated with
poorer prognosis in a variety of cancers. This has been linked to an increase in myeloidderived suppressor cell differentiation and activity, which suppresses inflammation
(Nakamura K. et al. 2018, Tangkijvanich P. et al 2007).

1.4

Overarching Hypothesis and Objectives

HPV infects the epithelium and avoids the immune system in order to establish and sustain
an infection. This results in chronic long-term infections that may last from months to even
years (Ramanakumar A. V. et al 2016). It is through these chronic infections that HPV can
drive the neoplastic transformation of cells in which they infect, resulting in cancers of the
mucosa, including those of the head and neck. I hypothesized that HPV’s suppression of
the proinflammatory activity of IL-18 not only contributes to viral evasion of the immune
system within the epithelium, but also contributes to maintenance of chronic HPV
infections that lead to HPV derived cancers.
In pursuit of my thesis’s overarching hypothesis, I undertook several different lines of
investigation. I explored the RNA and DNA methylation data within the TCGA, explored
the endogenous properties of HNSCC cell lines derived from both HPV+ and HPV-
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cancers, and performed biochemical assays exploring the effects of HPV’s major
oncoproteins on IL-18 expression. These objectives can be summarized as:
1. Utilize the RNA-seq and DNA methylation data within the TCGA to compare the
mRNA expression levels of IL-18 and other genes associated with this
inflammatory pathway in HPV+, HPV-, and normal non-cancerous tissues within
the head and neck.
2. Compare the mRNA and protein expression levels of IL-18 and IL-18BP between
HPV+ and HPV- HNSCC cell lines to determine if the IL-18 reduction seen within
the TCGA is also observed within HNSCC cell lines.
3. Determine if expression of the E7 oncogene, which is consistently expressed in
HPV+ cancers, is sufficient to repress transcription of the IL-18 gene.
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Chapter 2
Methods

2

2.1 TCGA RNA Expression and Analysis
Tumour and tissue samples from the head and neck cohort (HNSC) from the TCGA were
collected by researchers and health practitioners located across the globe (Cancer Genome
Atlas Network, 2015). These primary tumor samples were subjected to molecular
characterization, including mRNA-sequencing using the Illumina platform. The RNA
sequencing data was analyzed via a unified bioinformatic pipeline, and these results can be
freely downloaded from the Broad Genome Data Analysis Center Firehouse server
(https://gdac.broadinstitute.org/). The analysis pipeline used for all TCGA cohorts results
in level 3 RNA-seq by Expectation Maximization (RSEM) data that has been normalized
through RSEM normalization and encapsulates the mRNA content of over 22,000
expressed genes, allowing for comparisons across different tumor types and adjacent
normal control tissues collected at the time of tumour resection (Cancer Genome Atlas
Network, 2015). For this study, I performed a comparative analysis of eight genes in the
IL-18 pathway, including IL-18, IL-33, IL-1β, IL-18BP, CASP1, NLRP3, AIM2 and
PYCARD. The normalized mRNA expression values for each TCGA HNSC sample were
exported into Microsoft Excel for further organization and exported into additional
statistical software (details described below). In Excel, HPV status was manually
designated and derived from a previously published dataset (Bratman S. V. et al 2016).
Tumours derived from secondary metastatic lesions, as well as tumours with an unknown
HPV status were excluded from this study. This resulted in a total of 515 different tumours
available for analysis, with 73 HPV+ tumours, 442 HPV- tumours, and 43 samples from
normal adjacent tissues from this cohort. Statistical tests were conducted using GraphPad
Prism version 8.4 using a two-tailed non-parametric statistical T-tests, the Mann-Whitney
U test.

2.2

DNA Methylation Comparison

In addition to the mRNA-sequencing data, this study also used genome-wide DNA
methylation data obtained from the same TCGA HNSC cohort of cancer samples (Cancer
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Genome Atlas Network, 2015). This data was collected using the Illumina Infinium Human
Methylation450 Beadchip array, which encompasses over 450,000 methylation probes,
corresponding to CpG sites across the human genome. Like the RNA-sequencing data, the
normalized methylation values are publicly available from the Broad Genome Data
Analysis Center Firehouse server (https://gdac.broadinstitute.org/). There are 31 CpG
DNA probes within the IL-18BP upstream promoter region and 24 CpG probes within the
upstream promoter region of IL-18. These probes were identified using the online tool
Wanderer (Díez-Villanueva A. et al. 2015), which provides a digital representation of the
genome where CpG probes are identified within a given stretch of genomic DNA.
This methylation data is represented as β-Values, representing the fraction of CpG
methylated at that specific locus, and was exported into Microsoft Excel. These values
were manually curated for HPV status as described in section 2.1, and then used to
quantitatively compare the difference in methylation of the genomic DNA prior to the
beginning of IL-18 and IL-18BP gene respectively. This resulted in a total of 515 different
samples available for analysis, with 73 HPV+ tumours, 440 HPV-, and 23 samples from
normal adjacent tissues within these patients. Statistical tests were conducted using
GraphPad Prism version 8.4 using a two-tailed non-parametric statistical T-tests, the MannWhitneyU test.

2.3

Generation of Plasmids

Plasmids were generated using Polymerase Chain Reactions (PCR) to amplify the gene of
interest from a previously constructed template. PCR amplification of HPVs E7 was
conducted using Phusion Polymerase (ThermoFisher) with forward and reverse DNA
oligonucleotide primers (Integrated DNA Technologies, IDT) matching the beginning and
ending sequence of the gene of interest (Table 2.3). This PCR was completed using 10µM
of each primer, 10ng of template plasmid DNA, and 5xPhusion buffer (ThermoFisher) to
a final volume of 20µl. Reactions underwent 30 cycles of amplification, with an annealing
temperature of 60°C for 15 seconds, extension at 72°C for 20 seconds, and a release
temperature of 98°C for 20 seconds within a thermocycler (BioRad, C1000 Touch
Thermocycler). Ten microliters of this PCR reaction was loaded onto a 1% Agarose Gel
(FroggaBio) in gel running buffer (0.5x TBE) with 0.01% ethidium bromide and subjected
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to electrophoresis to confirm PCR amplification by the presence of a band of the predicted
size. Forty microliters of the PCR reaction were purified using the EZ-10 Spin Column
DNA Gel Extraction Minipreps Kit (BioBasic) according to the manufacturer’s protocol.
This purified PCR product and 1µg of the zsGreen circular plasmid (pLVX-3xTy1-T2AzsGreen supplied by Dr. Greg Fonseca) was then digested with XhoI and EcoRI-HF (NEB)
within CutSmart buffer (NEB) at a final volume of 20µl for 1 hour at 37°C, with 1 unit of
each enzyme. The digested plasmid was then loaded and run within a 2% agarose gel
(FroggaBio) with ethidium bromide as described above for confirmation of linearization,
and the band of interest was then cut for further purification using the EZ-10 Spin Column
DNA Gel Extraction Minipreps Kit (BioBasic). Both the digested plasmid and the digested
PCR product were then purified again in preparation for ligation using Quick Ligase
Enzyme (NEB) and Quick Ligase x2 Buffer for 10 minutes at room temperature.
To construct our IL-18 promoter luciferase vector, we amplified a fragment of DNA
containing the promoter region of IL-18 purchased from IDT. This construct corresponds
to the 1.5kb region of DNA immediately prior to the IL-18 gene. PCR amplification was
performed using a Q5 Polymerase (NEB) with 10µM of each primer (Forward and reverse
E7 primer for cloning, Table 2.4), 10ng of template plasmid DNA, and 5xPhusion buffer
to a final volume of 50µl. This reaction underwent 15 cycles of amplification using an
annealing temperature of 67°C for 30 seconds, extension temperature of 72°C for 20
seconds, and a release temperature of 98°C. Ten microliters of this PCR reaction was
loaded into a 1% Agarose Gel (FroggaBio) with ethidium bromide for electrophoresis to
confirm PCR amplification. Forty microliters of the PCR reaction were purified using the
EZ-10 Spin Column DNA Gel Extraction Minipreps Kit (BioBasic) according to the
manufacturer’s protocol. This purified PCR product and 1µg of pGL3-Basic circular
plasmid obtained from the laboratory of Dr. Fred Dick in the Victoria Research Labs (VRL)
at Victoria Hospital., was then digested with XhoI-HF and KpnI-HF within CutSmart
buffer (NEB) at a final volume of 20µl for 1 hour at 37°C. The digested plasmid was then
loaded and run within a 1% agarose gel with ethidium bromide for confirmation of
linearization, and the band of interest was then cut for further purification. Both the
digested plasmid and the digested PCR product were then purified again in preparation for
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ligation. Ligation was conducted using Quick Ligase Enzyme (NEB) and Quick Ligase x2
Buffer for 10 minutes at room temperature.
Plasmids 7-24 (Table 2.1) were developed by previous PhD student Dr. Biljana Todorovic
and are described in her previous publication (Todorovic B. et al 2011). These plasmids
were digested to extract the gene fragments of interest and then ligated into a plasmid
vector containing an N-terminal GFP and a myc tag (Table 2.2)
All plasmids were transformed into the bacterium Escherichia coli (strain DH5ɑ) and
subsequently plated onto lysogeny broth (LB, 10g/L tryptone, 5g/L yeast extract, 86mM
NaCl) plates with ampicillin selection (50µg/ml, BioShop). The resulting colonies were
screened for proper transformation and ligation of the insert through colony PCR and
PureLink Quick Plasmid Miniprep kits. Briefly, colonies were picked under sterile
conditions using a p200 pipette tip. The tip was dipped within a prepared Phusion
polymerase reaction. This PCR was completed using 10µM of each primer to the respective
insert (Table 2.4), the picked colony of bacteria as the source of template plasmid DNA,
and 5xPhusion buffer to a final volume of 50µl. This reaction underwent 30 cycles of
amplification, with an annealing temperature of 60°C for 15 seconds, extension
temperature of 72°C for 20 seconds, and a release temperature of 98°C. The entire PCR
product was then loaded into a 1% agarose gel with ethidium bromide and electrophoresed
to confirm PCR amplification of the insert. The p200 pipette tip used to pick the colony
was also submerged in 5ml of liquid LB + ampicillin solution and incubated for 16 hours
(overnight) at 37°C to make a small preparation of the plasmid DNA. The small-scale
plasmid preparations of the plasmids in which the colony PCR was positive were done
using the manufacturer’s instructions for the PureLink Quick Plasmid Miniprep kits
(Geneaid). These plasmids were sent for sequencing at the BioBasic facility in Burlington,
Ontario where the samples underwent Sanger sequencing for sequence confirmation.

2.4

Cell Culture and Transfection

HT1080 fibrosarcoma cells were used for testing expression from recently cloned
expression vector plasmids and for co-transfections. The HNSCC cell lines PE/CA, Cal27,
Cal33, PIC6B, SCC2, SCC9, SCC47, SCC61, SCC152, UWO8, UWO23, UWO37, FaDu,
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and 93-VU (Table 2.3) were used as a source of mRNA for qPCR assays of gene expression
and protein for western blotting. Cal33 cells were also grown and transfected with
expression vectors for HPV oncogenes and luciferase assays. These cell lines were
generously shared with me from the laboratory of Dr. Anthony Nichols (Western
University), with Dr. John Barret generating the UWO series of HNSCC HPV+ cell lines.
HT1080 cells were cultured in Dulbecco’s modified eagle medium (DMEM) with 10%
fetal bovine serum (FBS) supplemented with 100µg/mL streptomycin and 100
international units (IU) per ml of penicillin. All cells were cultivated in T75 adherent tissue
culture flasks (Sarstedt) within an incubator at 37°C with 5% CO2. Cells were harvested
and split through washing with phosphate buffered saline (PBS; Wisent) then incubated in
1ml of a 0.25% trypsin/EDTA solution (Wisent) to release the cells from the adherent
flasks.
For HT1080 transfections, cells were seeded and cultivated within 10cm adherent cell
culture plates (Sarstedt) and grown until ~80% confluency. Medium was replaced with
fresh DMEM with 10% FBS, and cells were then transfected with 8µg of zsGreen-HPV16
E7 using the transfection reagent X-tremeGene DNA Transfection Reagent (Roche). These
transfections were completed by mixing a ratio of 2µl of transfection reagent with 1µg total
of plasmid DNA in 1ml of serum-free cell culture media. Cells were incubated with the
transfection reagent for 24h and expression was confirmed by fluorescent microscopy.
Cal33 head and neck cancer cells were selected for the luciferase assays as they expressed
high levels of IL-18 mRNA and are HPV- (Table 2.3). These cells were cultivated in
Dulbecco’s modified eagle medium/Hams nutrient mixture F12 (DMEM/F12) with 10%
FBS with 100µg/mL streptomycin and 100IU of penicillin. in T75 adherent tissue culture
flasks (Sarstedt) within an incubator at 37°C with 5% CO2. Cells were harvested and split
through washing with PBS (Wisent) then incubated in 1ml of a 0.25% trypsin/EDTA
solution (Wisent) to release the cells from the adherent flasks. Cal33 were seeded within
6-well adherent cell culture plates and grown until ~80% confluency. Medium was
replaced with fresh DMEM/F12 with 10% FBS and cells were transfected with a total of
5µg of DNA using Lipofectamine 3000 adherent cell culture transfection reagent
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(ThermoFisher). This was done with 7.5µl of transfection reagent and 2µl of p3000 reagent
per 1µg of DNA. Cells were transfected with 5µg of zsGreen-HPV16 E7 for the purposes
of qPCR, western blot, and ELISA. Cells were transfected with 2.5µg of pGL3-Basic-IL18 promoter with 2.5µg of one of the pCANmyc-EGFP E7 constructs for luciferase assays
(Table 2.2). Cells were incubated with the transfection reagent and DNA for 10 hours, then
the transfection media was replaced with fresh DMEM/F12 for an additional 38 hours of
incubation. Transfection and expression were confirmed through the use of fluorescent
microscopy. The microscope used was the Nikon Eclipse Ti with the fluorescent light
supplied through the Nikon Intensilight C-HGFI Unit. Images were captured using a Retiga
EXi FAST Cooled mono 12-Bit camera and then processed through the Volocity 6.1.1
Image software

2.5

Quantitative Reverse Transcription PCR

HNSCC cell lines were harvested upon reaching 80% confluency. Media was removed by
aspiration and cells were washed with 1ml of cold PBS. One milliliter of cell lysis buffer
(sourced from NEB) with protease inhibitor was applied to each plate and cells were
harvested using a cell scraper. The cells were incubated with lysis buffer at 4°C for 10
minutes. RNA was collected using the Monarch Total RNA Miniprep Kit (NEB) with
PureLink DNase (ThermoFisher). cDNA was obtained by reverse transcription of 1µg of
RNA utilizing the SuperScript VILO cDNA Synthesis kit (ThermoFisher). The
quantification of IL-18 and IL-18BP RNA was completed using the TaqMan Gene
Expression Assay (ThermoFisher) according to the manufacturer’s protocol with 100ng of
cDNA. Analysis of expression was performed through the quantification of the -ΔΔCT
values calculated by RT-qPCR and standard curves. Standard curves were established
through the serial dilution of a plasmid containing the DNA sequence matching the mature
mRNA sequence of IL-18, IL-18BP, E7, and GAPDH. 100ng, 10ng, 1ng, 0.1ng, and
0.01ng of DNA standards were analyzed using the TaqMan Gene Expression Assay
(ThermoFisher) according to the manufacturers protocol. The -ΔΔCT values were then
subsequently plotted to establish a standard curve. The plasmid has a known size in base
pairs, and together with the slope of the standard curve I was able to ascribe a DNA copy
number to the given CT values. As qPCR probes are dependent on the quantity of DNA in
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the sample, we are able to apply this standard curve to the given CT values of our cellular
mRNA made cDNA.

mRNA content =

2.6

(Slope ∗ avgΔΔCT + yintercept) ∗ 6.022 ∗ 1023 molecules/mole
660g
(Plasmid base pairs ∗
) ∗ 1 ∗ 109 ng/g
mole

Western Blot

Protein samples were prepared through the lysis of cells with RIPA buffer at 4°C for 15
minutes. Cells were then gently centrifuged for 10 mins at an RCF of 500xg at 4°C to pellet
cell debris, and the supernatant was removed. Twenty microliters of the cell lysate were
then mixed with LDS loading buffer ([2xLDS buffer, 1,4-Dithiothreitol (DTT)] Novex).
Samples were initially loaded into a NuPage 10% Bis-Tris polyacrylamide gel (Invitrogen).
These samples were resolved by electrophoresis at 200V in MES running buffer (50mM
MES, 50mM Tris, 3.47mM SDS, 1.03 EDTA, BioShop). The proteins within the gel were
then transferred into a 0.45µm pore polyvinylidene fluoride membrane (PVDF; FroggaBio)
using the XCell SureLock docking system (Invitrogen) using our own custom transfer
buffer (25mM Bicine, 25mM Bis-Tris, 1.03 EDTA, 20mM chlorobutanol, 10% methanol.
Bicine from BioBasic, remaining reagents from BioShop). Before protein transfer, the
PVDF membrane was “activated” by a brief soak in methanol. Protein transfer from the
gel to the membrane was done at 18V for 1.1 hours. After transfer, the PVDF was briefly
soaked in TBS-T (Tris buffered saline [20mM Tris, 136mM NaCl] with 0.1% Tween-20:
Tween-20 from Sigma, the rest from BioShop). The membrane was subsequently blocked
with skim milk blocking buffer (5% w/v Skim Milk Powder in TBS-T) for an hour at room
temperature. The membrane was then incubated overnight in blocking solution containing
the primary antibody (Table 2.1). The membranes were then washed thrice for 20 mins at
room temperature with TBS-T. The membrane was then gently shaken for an hour with a
secondary antibody (Table 2.1), a species-specific monoclonal antibody conjugated with
horseradish peroxidase (HRP) and diluted in blocking buffer. After three further 20-minute
washes with TBS-T at room temperature, the membrane was then treated with Immobilon
Luminata Crescendo Western HRP Substrate or Immobilon Luminata Forte Western HRP
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Substrate (Millipore) for two minutes. Images were obtained using the ChemiDoc XRS
Gel Imaging system and software (BioRad).

2.7

Bradford Assay

The concentration of protein in cell extracts was determined using the Bradford assay dye
reagent (BioRad). Serial dilutions of bovine serum albumin (BSA, Sigma) were used to
create protein standards containing 1, 2, 5, 10, and 40µg/ml of BSA in double distilled
water (ddH2O). One microliter of these standards was added ddH2O to a final volume of
800µl and mixed with 200µl of the 5x Protein Assay Dye Reagent (BioRad). Two hundred
microliters of this final solution were added to the wells of clear flat bottomed 96-well
plates (ThermoFisher) in technical duplicates. Using a Multiscan Ascent plate-reader
(ThermoFisher) at 450nM, the absorbance values were measured and plotted to develop
the standard curve utilized in protein concentration calculations.

2.8 Sandwich Enzyme Linked Immunosorbent Assay
(ELISA)
HNSCC cell lines were cultivated in 10cm cell culture dishes until ~80% confluency. Cell
culture media was replaced with fresh media, which was collected 24 hours later. Media
was centrifuged at an RCF of 500xg for 10 minutes at 4°C to pellet cellular debris, which
was discarded. Cells were collected from the plates with a scraper and counted using a
hemocytometer. Two hundred microliters of the cell culture media were incubated in
duplicate with IL-18 specific antibody coated wells upon a plate shaker at 200rpm at 4°C
overnight (Abcam). These plates then had the media aspirated and underwent 3 rounds of
washing with PBS. The plates then underwent a secondary incubation period shaking at
500rpm at room temperature with the supplied secondary antibody conjugated to HRP. The
wells were then again washed 3 times with PBS and were then activated through the
addition of a TMB development substrate and shaking at 500rpm in complete darkness for
10 minutes. The plates OD values were then collected using the Multiscan Ascent platereader (ThermoFisher) at 450nm.
Lyophilized recombinant IL-18 (Abcam) was used as a protein standard. A series of
dilutions of IL-18 were created at 8000pg/ml, 4000pg/ml, 2000pg/ml, 1000pg/ml,

34

500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, and a sample containing no recombinant IL18. These serial dilutions were subjected to analysis by ELISA as described above to
generate a standard curve.

2.9

Luciferase assay

Three hundred thousand Cal33 cells were seeded within 6-well plates. After 24 hours, they
were transfected with the IL-18 luciferase reporter vector and either a control vector or a
vector expressing an HPV oncoprotein using lipofectamine 3000. The cells were then
incubated for 10 hours before the transfection media was removed by aspiration. Cells were
washed using 1ml of room temperature PBS and collected using a cell scraper. Cells were
pelleted by low speed centrifugation and the pellet was incubated in 200 µl of 1x Cell Lysis
Buffer (Promega) at 4°C for 10 minutes. Cell lysates were centrifuged at an RCF of 200xg
at 4°C for 10 minutes to pellet cell debris and the supernatant was collected. 50µl of cell
lysate was mixed with 100ul of luciferase assay substrate (Promega) immediately before
analysis using the Lumat LB 9507 luminometer (Bertold Instruments) to measure
luminescence. Measurements were taken immediately after mixing with a 10 second
measurement time. Twenty microliters of cell lysate were kept for confirmation of HPV16 E7 expression by Western Blot as described above. Relative light units (RLU) values
normalized based on protein levels as determined by the Bradford Assay.
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Table 2.1: List of antibodies used within this thesis
Antibody

Animal of
Origin
Anti- HPV- Mouse
16E7
polyclonal
Anti-IL-18
Mouse
polyclonal
Anti-ILRabbit
18BP
polyclonal
Anti-Tubulin Mouse
polyclonal
Anti-Mouse
Rat
antibody
monoclonal
(IgG)
Anti-Rabbit
Goat
antibody
polyclonal
(IgG)
Anti-c-Myc
Mouse
monoclonal

Usage

Dilution factor

Company

WB, primary
conjugated HRP
WB, primary antibody

1:500

SantaCruz

1:1000

AbCam

WB, primary antibody

1:1000

AbCam

WB, primary antibody

1:2000

Sigma

WB, secondary for IL- 1:20000
18 and tubulin,
conjugated to HRP
WB, secondary for IL- 1:20000
18BP, conjugated to
HRP
WB, primary antibody 1:2000

Jackson
Laboratories
Jackson
Laboratories
Invitrogen
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Table 2.2: List of plasmids used within this thesis
#
1

Name
pCANmyc-EGFPhIL18

Backbone
pCANmyc-EGFP

2

pCANmyc-EGFPhIL18BP

pCANmyc-EGFP

3

pGEM-GAPDH

pGEM

4

pCANmyc-EGFP

pCANmyc-EGFP

5

pGL3-Basic

pGL3-Basic

6

pGL3-Basic

7

pGL3-Basic-IL18promoter
HPV16-E7

8

HPV6-E7

pCANmyc-EGFP

9

HPV11-E7

pCANmyc-EGFP

10 HPV18-E7

pCANmyc-EGFP

11 HPV31-E7

pCANmyc-EGFP

12 HPV35-E7

pCANmyc-EGFP

13 HPV39-E7

pCANmyc-EGFP

pCANmyc-EGFP

Description/insert
Plasmid containing an exon-exon
junction within the transcribed IL-18
mRNA sequence for qPCR standard
curve production
Plasmid containing an exon-exon
junction within the IL-18BP genomic
sequence for qPCR standard curve
production
Plasmid containing an exon-exon
junction within the GAPDH genomic
sequence for qPCR standard curve
production
Plasmid containing EGFP behind a
multiple cloning site
Plasmid containing a promoterless
luciferase gene
Plasmid containing luciferase vector
with the 1.5kb IL-18 promoter region
HPV-16 E7 ligated to EGFP, used for
the amplification, and cloning of E7,
transfection of E7, and cotransfection of E7 and luciferase
vector
HPV-6 E7 with N-terminal myc-tag
for co-transfection of E7 and
luciferase vector
HPV-11 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-18 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-31 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-35 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-39 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
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14 HPV45-E7

pCANmyc-EGFP

15 HPV52-E7

pCANmyc-EGFP

16 HPV55-E7

pCANmyc-EGFP

17 HPV58-E7

pCANmyc-EGFP

18 HPV59-E7

pCANmyc-EGFP

19 HPV67-E7

pCANmyc-EGFP

20 HPV74-E7

pCANmyc-EGFP

21 HPV16-E7 CR1-2
aa1-39
22 HPV16-E7
CR3
aa39-98
23 HPV16-E7
CR3
Binding Domain 1
aa39-58
24 HPV16-E7
CR3
Binding Domain 2
aa58-99
25 pEGFP-C2

pCANmyc-EGFP

26 pLVX-3xTy1-T2AzsGreen

pLVX-3xTy1-T2AzsGreen

27 pLVX-3xTy1-T2AHPV16-E7

pLVX-3xTy1-T2A

pCANmyc-EGFP
pCANmyc-EGFP

pCANmyc-EGFP

pEGFP-C2

HPV-45 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-52 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-55 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-58 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-59 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-67 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-74 E7 with N-terminal myc tag
for co-transfection of E7 and
luciferase vector
HPV-16 E7’s conserved regions 1
and 2 aa1-39 with N-terminal EGFP
HPV-16 E7’s conserved region 3
aa39-98 with N-terminal EGFP
HPV-16 E7’s conserved region 3
with its first binding domain aa39-58
with N-terminal EGFP
HPV-16 E7’s conserved region 3
with its second zinc-binding domain
aa59-98 with N-terminal EGFP
GFP
vector
for
transfection
efficiency
Empty
vector
with
zsGreen
fluorescent protein behind a multiple
cloning site with a T2A self-cleavage
site
HPV-16 E7 ligated to zsGreen
through a T2A self-cleavage site for
transfections and luciferase assays
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Table 2.3: List of cell culture cell lines utilized in this thesis
All cell lines are HNSCC cell lines and were cultivated in DMEM/F12 with 10%FBS and
1% Pen/Strep with the exception of HT1080 cell lines which are fibrosarcoma and were
cultivated in DMEM with 10% FBS and 1% Pen/Strep
Cell Line

Cell Line HPV Status

HT1080

HPV-

CAL33

HPV-

CAL27

HPV-

SCC2

HPV+

SCC9

HPV-

SCC40

HPV-

SCC47

HPV+

SCC61

HPV-

SCC152

HPV+

PIC6B

HPV-

PE/CA

HPV-

93-VU

HPV+

FaDu

HPV-

UWO8

HPV+

UWO23

HPV+

UWO37

HPV+
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Table 2.4: List of oligonucleotide ssDNA primers used within this thesis
Primer Name

Primer Sequence 5’-3’

GAPDH Forward
primer
GAPDH Reverse
primer
IL-18
Forward
Primer
IL-18
Reverse
Primer
IL-18BP Forward
Primer
IL-18BP Reverse
Primer
HPV-16
E7
Forward Primer
HPV-16
E7
Reverse Primer
HPV-16
E7
Forward Primer
HPV-16
E7
Reverse Primer
IL-18 Promoter
region
forward
primer
IL-18 Promoter
region
reverse
Primer
pGL3-Basic
Forward Primer
pGL3-Basic
Luciferase gene
Reverse Primer
CMV promoter
Forward primer

ATGACAACTTTGGTATCGTGGAAGG

Primer
Usage
qPCR

GAAATGAGCTTGACAAAGTGGTCGT

qPCR

CCTGGAATCAGATTACTTTGGC

qPCR

GGGTGCATTATCTCTACCAGTCAGA

qPCR

CCAGTGTTCCCAGCAGCTAA

qPCR

CTGCAGGCCACACAGGATAA

qPCR

ACAGCTCAGAGGAGGAGGAT

qPCR

ACCGAAGCGTAGAGTCACAC

qPCR

TATACTCGAGATGCATAGGAGATACA

Cloning

TATACTTAAGTGGTTTCTGAGAACAGATG

Cloning

TATGGTACCCTACTTGATCCCACTTCGTGCTT Cloning
TC
TATACTCGAGCTCCAGCAAGCTGGGGAGAG

Cloning

CAAAACGAAACAAAACAAACTAGC

Sequencing

GCGGTTCCATCTTCCAGCGG

Sequencing

GGCGTGTACGGTGGGAGGTC

Sequencing
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Chapter 3

3

Results

3.1 Investigation of the Impact of HPV on the IL-18 Pathway
Using the TCGA Head and Neck Cancer Cohort
The data obtained by the TCGA represents a powerful opportunity to undertake a
bioinformatics-based analysis of the impact of HPV on the IL-18 pathway in head and neck
cancer. Specifically, this allows us to utilize at a wide array of processed and analyzed
samples of real head and neck tumours from across the globe. In the head and neck cohort
of the TCGA, the HPV status was also previously determined (Bratman S. V. et al 2016,
Cancer Genome Atlas Network, 2015) resulting in a pool of 73 HPV+ cancers, 442 HPVcancers, and 43 samples of normal, non-cancerous adjacent tissues extracted along with
patient tumours. These normal adjacent tumours are tissues samples excised from patients
in addition to their primary tumour and represent non-cancerous tissue from the same
tumour location. This allows us to compare our HPV+ cancers to the non-cancerous tissues
that surround it as a normal control.
To explore the expression of IL-18 and its associated pathway constituents, I used both the
transcriptomic database as well as the database of genomic methylation data from the head
and neck cohort of the TCGA. The transcriptomic data contains the normalized mRNA
content of the tumours and normal adjacent tissues, which allows for the quantitative
analysis of changes in mRNA expression between individual tumour samples and normal
adjacent tissues. The genomic methylation database contains β-values, which represent
proportional DNA methylation of CpG sites located throughout the human genome,
allowing for quantitative analysis of changes in methylation of genes between HPV+,
HPV-, and normal adjacent tissues.

3.1.1

The Impact of HPV status on the Expression of IL18 and
Related Proinflammatory Cytokines in Primary Human Head
and Neck Cancers

We initially began our investigation by examining expression of IL-18’s inhibitory protein
IL-18BP and IL-18 itself. Previously, In vitro cell culture analysis conducted by the
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MacDonald laboratory at Leeds University has shown an increase in the production of IL18BP by human foreskin keratinocytes in response to introduction of HPV’s oncogenes
(Richard K. H. et al 2013). To see if this increase in IL-18BP the MacDonald lab
discovered was mirrored in real cancers, I turned to the TCGA for answers. These findings
are similarly present in the TCGA HNSCC cohort, as there is a significant increase in the
expression of the IL18BP gene’s mRNA in HPV+ cancers when compared to HPV- cancers
and normal adjacent tissue (Figure 3.1A).
Next, I examined the expression of IL18 mRNA to see if there were any additional
alterations to the IL-18 pathway in these HPV+ cancers. Here I found that it was
significantly reduced in HPV+ cancers when compared to HPV- cancers and normal
adjacent tissues (Figure 3.1B). IL-18 is one of three proinflammatory cytokines within the
IL-1 family of cytokines, so we also examined expression of the other constituents of the
IL-1 family, IL-1β and IL-33. The mRNA levels of IL1β, while reduced in HPV+ cancers
when compared to HPV- cancers, were not significantly different when compared to
normal adjacent tissues (Figure 3.1C). The mRNA levels of IL33 were significantly
reduced in both HPV+ and HPV- cancers when compared to normal adjacent tissue, but
the two cancer types had comparable levels of cytokine transcription (Figure 3.1D). Thus,
of the three members of the IL-1 family of proinflammatory cytokines, only IL18 mRNA
expression is significantly reduced in HPV+ cancers compared to the expression of normal
adjacent tissues or HPV- cancers, suggesting a targeted reduction in IL-18’s activity by
HPV (Figure 3.1).
The head and neck can be divided into different subsites, including the oropharynx, the
alveolar ridge, oral cavity, larynx, and hypopharynx. It is well established that patient
outcome and survival is improved in HPV+ HNSCC within the oropharynx when
compared to HPV- oropharyngeal cancer (Ang K. K. et al 2010, Burr A. R., et al 2018).
We compared the expression of IL18 in the 73 HPV+ cancers across the anatomical
subsites to see if the expression of IL18 could be correlated to the varied changes in patient
outcome in HPV+ cancers of the oropharynx compared to the other head and neck subsites.
One sample was excluded from the HPV+ cancers, as the anatomical head and neck subsite
was not clarified. There was no significant difference in IL18 expression between the
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anatomical subsites of HPV+ head and neck cancers, suggesting that HPV represses IL-18
across all anatomical subsites, though due to low sample number there is a noticeable lack
of statistical power when comparing the different head and neck subsites (Figure 3.2A).
In the sphere of HPV+ cancers, HPV-16 is the most prevalent HPV type found within
HPV+ head and neck cancers as well as cervical cancers (D’Souza G. et al 2010). As
different types of HPV are identified in the head and neck cohort of the TCGA, I next
examined the expression of IL18 between samples grouped by the different types of HPV
to examine if the repression of IL18 is found across HPV types to explore if the repression
of IL-18 could contribute to the heightened success of HPV-16 in establishing long-term
oncogenic infections compared to the rarer HPV types. There was no difference in IL18
expression between the different HPV types suggesting the repression of IL18 is a
conserved function among the high-risk HPV within the head and neck cancers (Figure
3.2B).

3.1.2

Impact of HPV on The Expression of the Inflammasome
Components AIM2, PYCARD, NLRP3, and CASP-1 in
Primary Human Head and Neck Cancers

As previously mentioned, for IL-18 to be rendered biologically active it must be cleaved
by active capsase-1. The activation of caspase-1 is the result of stimulated PRRs and the
formation of a complex of proteins called the inflammasome. Two distinct types of
inflammasomes induce caspase-1 activation. These include the AIM2 inflammasome in
response to detection of dsDNA in the cytoplasm, or the NLRP3 inflammasome in response
to various cellular stresses like microbial infection, reactive oxygen species, cellular
dysfunction, and cellular damage (Kelley N. et al 2019). We looked at the impact of HPV
on expression of the genes encoding the constituents of these inflammasomes, including
NLRP3, the AIM2 encoded PRR and the adaptor protein ASC (encoded by the PYCARD
gene), which allows for caspase-1 binding to both AIM2 and NLRP3. With regards to the
AIM2 inflammasome, there is no significant difference in the expression of AIM2 mRNA
between the HPV+ and HPV- cancers, although expression was elevated in both cancers
when compared to normal adjacent tissue (Figure 3.3A). Expression of both PYCARD and
CASP1 mRNAs were both significantly reduced in HPV+ cancers when compared to HPV-
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cancers, although PYCARD mRNA levels were not different compared to the normal
adjacent tissue (Figure 3.3B/C). There is no apparent change to in levels of NLRP3 mRNA
as there was no significant difference between HPV+, HPV- and the normal adjacent tissue
(Figure 3.3D). Taken together, these data suggest that another potential means of IL-18
suppression by HPV could be mediated through the reduced expression of two vital
components of IL-18 activation, caspase-1 and its adaptor protein ASC, which are both
needed for the AIM2 and NLRP3 inflammasome (Figure 3.3A-C).
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Figure 3.1: Expression of mRNAs encoding IL-18, IL-18BP and related cytokines in
tumor samples from the TCGA head and neck cancer cohort.
The mRNA expression levels of IL18BP (A), IL18 (B), IL33 (C), and IL1β (D) were
compared between HPV+, HPV- tumours, and non-cancerous adjacent tissues from TCGA
HNSCC patient data. (A) There was significantly more IL-18BP mRNA in HPV+ cancers
when compared to HPV- cancers and normal adjacent tissues. (B) There was significantly
less IL18 mRNA in HPV+ cancers compared to HPV- cancers and normal adjacent tissues.
(C) There was significantly less IL1β mRNA in HPV+ cancers compared to HPV- cancers
but there was no significant difference between HPV+ cancers and normal adjacent tissue.
(D) There was significantly less IL33 mRNA in HPV+ cancers then compared to normal
adjacent tissues but there was no significant difference between HPV+ and HPV- cancers.
Statistical analysis was conducted through a Non-parametric Mann-WhitneyU test
(p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns).
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Figure 3.2: Expression of mRNAs encoding IL-18 in HPV+ samples from the TCGA
head and neck cancer cohort.
(A) Comparing the expression of IL18 between the anatomical subsites identified no
significant difference between the oropharynx and the other head and neck cancer sites.
(B) There was also no significant change in expression of IL18 between HPV-16+ head
and neck cancers and those cancers caused by other HPV types. Statistical analysis was
conducted through a Non-parametric Mann-WhitneyU test (p<0.0001=****,
p<0.001=***, p<0.05=*, p>0.05=ns).
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Figure 3.3: Impact of HPV on expression of the genes encoding caspase-1 and
components of the inflammasomes that activate caspase-1.
The mRNA levels of the components of the inflammasome CASP1 (A) PYCARD (B),
AIM2 (C), and NLRP3 (D), were calculated for HPV+ tumours, HPV- tumours, and noncancerous adjacent tissues from patient data within the TCGA head and neck cancer cohort.
(A) There was significantly less CASP1 mRNA in HPV+ cancers compared to HPVcancers and normal adjacent tissues. (B) There was significantly less PYCARD mRNA in
HPV+ cancers compared to HPV- cancers but there was no significant difference between
HPV+ cancers and normal adjacent tissues. (C) There was no significant difference in
AIM2 mRNA between HPV+ cancers and HPV- cancers but it was significantly higher in
both cancer types compared to normal adjacent tissues. (D) There was no difference in
NLRP3 expression across HPV+ cancers, HPV- cancers, and normal adjacent tissues.
Statistical analysis was conducted through a Non-parametric Mann-WhitneyU test
(p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns).
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3.1.3

DNA Methylation Status of CpG Sites Upstream of the IL18
Gene’s Open Reading Frame in Primary Human Head and
Neck Cancers

DNA methylation is a well-documented mechanism of control over gene expression, with
higher levels of DNA methylation at CpG sites within the genome upstream of the start of
a gene being associated with lower transcription and gene expression (Moore L. D. et al
2013). HPV E7 has been previously shown to alter transcription of host genes by
associating with and activating the DNA methyltransferase protein DNMT1, leading to
changes in DNA methylation (Verlaat W. et al. 2018, Widschendter A. et al. 2004). We
utilized the TCGA’s DNA methylation data to determine if there was a change in DNA
methylation up-stream of the IL18 locus HPV+ HNSCC. We collected data from 24 DNA
probes surrounding the IL18 coding region on chromosome 11 (Figure 3.4A), which
provided β-values representative of proportional methylation for each site in each cancer
sample. Methylation of CpG sites in the upstream region of the IL18 gene in HPV+ cancers
exhibited significantly higher levels of methylation compared to their HPV- cancers and
normal adjacent tissue counterparts (Figure 3.4B-Y). Increased methylation across these
CpG sites may represent a possible mechanism leading to the transcriptional repression in
HPV+ HNSCC. The first four probes prior to the IL18 gene, probes cg11304234,
cg26534425, cg04929355, cg09122223, (Figure 3.4 C-F) exhibit the largest increases in
the levels of DNA methylation in HPV+ cancers, and are within 1.5kb of the start of IL18’s
gene. This section of DNA was the selected for usage within luciferase assays presented in
section 3.3.
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Figure 3.4: Probe location and β-values for CpG methylation within the 5’ promoter
region of the IL-18 gene
(A) A map of the section of chromosome 11 and the locations of the CpG sites and their
corresponding DNA probes with respect to the IL18 gene. (B-Y) The β-values for CpG site
methylation for the indicated DNA probes were extracted from the TCGA Illumina
BeadChip Array data. These values were calculated for HPV+ tumours, HPV- tumours,
and non-cancerous adjacent tissues from patient data within the TCGA head and neck
cohort. Statistical analysis was conducted through a Non-parametric Mann-WhitneyU test
(p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns).
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3.2 Examining Expression of IL-18 and IL-18BP in HNSCC
Cell Lines
3.2.1

The Effect of HPV Status on IL-18 and IL-18BP Levels in
HNSCC Cell Lines

Analysis of the TCGA data showed a significant decrease in IL-18 mRNA and significantly
increase IL-18BP mRNA levels in HPV+ primary human head and neck cancers when
compared to HPV- cancers and regular tissues. I next tested a panel of established HNSCC
cell lines to determine if HPV status was similarly correlated with reduced IL-18
expression and increased IL-18BP expression. These cell lines were generated from
excised patient tumours, that through mutation of their biological processes have escaped
typical cellular senescence and are able to be grown in vitro. These cell lines are all derived
from the head and neck, with the HPV+ cell lines containing integrated HPV DNA within
their genome. The UWO series of cell lines were generated within the Nichols laboratory
by Drs. Anthony Nichols and John Barret and were generously shared with me for my
experiments. We hypothesized that if the biological phenomenon of IL-18 repression and
IL-18BP upregulation was mirrored in these cell lines, this would allow us to use these cell
lines as an experimental system for the investigating the mechanism by which HPV affects
expression of IL-18 and its associated pathway components.
I initially began our investigation into IL-18 and IL-18BP expression in HNSCC cell lines
using qPCR to examine the levels of IL18 and IL18BP mRNA. I extracted cellular mRNA
and converted it to cDNA, which was used for qPCR. I found that HPV+ HNSCC cell lines
expressed significantly less IL18 mRNA than HPV- cell lines (Figure 3.5A). Regarding
IL18BP, I found a significantly greater production of IL18BP mRNA in HPV+ cell lines
compared to HPV- cell lines (Figure 3.5B).

3.2.2

The Effect of HPV Status on Expression of IL-18 and IL18BP Protein and Secretion in HNSCC Cell Lines

To corroborate the mRNA expression level data obtained from our HNSCC cell cultures,
I also examined the expression of IL-18 and IL-18BP protein. Cell lysates were collected
for western blot analysis, while the cell culture media was collected for analysis by ELISA.
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In the western blot analysis, IL-18 was detected in the HPV- cell lines but was barely
detectable in most of the HPV+ tumor cell lines, with the noticeable exception of SCC47
(Figure 3.6A). The α-tubulin protein was used as a control to ensure uniform loading of the
protein gels. I also used a sandwich ELISA to measure the level of secreted IL-18 in the
cell culture media. There were significantly lower concentrations of secreted IL-18 in the
HPV+ cell culture media when compared to the cell culture media of the HPV- cell lines
(Figure 3.6B). Thus, these cell line studies suggest that HPV represses IL-18 mRNA
expression and protein production in most established HNSCC cells, in good agreement
with the reduction in mRNA observed using the TCGA data obtained from primary head
and neck tumors (Figure 3.1B). Unfortunately, no IL-18BP could be detected by either
western blot or ELISA.
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Figure 3.5: mRNA analysis of IL-18 and IL-18BP in established HNSCC cells lines.
The mRNA levels of IL-18 (A) and IL-18BP (B) was measured by qPCR in HPV+
(SCC2, SCC47, SCC152, 93-VU, UWO23, UWO37) and HPV– (Cal33, PE/CA, SCC9,
SCC40, SCC61, PIC6B, FaDu) HNSCC cell lines to determine the impact of HPV status
on expression. (A) Significantly lower levels of IL-18 mRNA were detected in HPV+
HNSCC cell lines when compared to the HPV-cell lines (p<0.05, p=0.0309). (B)
Significantly higher levels of IL-18BP mRNA were detected in HPV+ HNSCC cell lines
when compared to the HPV-cell lines. Statistical analysis was conducted through a Nonparametric Mann-WhitneyU test (p<0.05, p=0.0262).
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Figure 3.6: Analysis of IL-18 protein expression levels in established HNSCC cell
lines.
I measured the protein levels of IL-18 (A) and ɑ-tubulin (B) in HNSCC cell lines by
western blot and secreted IL-18 by ELISA (C) in HPV+ (SCC2, SCC47, 93-VU, UWO23,
UWO37) and HPV– (Cal33, PE/CA, SCC9, SCC61, PIC6B, FaDu) HNSCC cell lines to
determine the impact of HPV status on expression. Western blots of the HNSCC cell lysate
for (A) IL-18 to examine intracellular IL-18 with ɑ-tubulin as a loading control.
Intracellular IL-18 was nearly indetectable in HPV+ cells while most HPV- cells have
consistently detected IL-18. (B) Using an ELISA to detect secreted IL-18 in cell culture
media, there was significantly lower levels of IL-18 protein were detected in HPV+
HNSCC cell lines when compared to the HPV-cell lines (p<0.05, p=0.0286). Western blots
and ELISA of IL-18BP protein failed to yield a detectable signal
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3.3 Determining the Effects of HPV E7 on IL18 Transcription.
3.3.1

The Effect of HPV16’s E7 on the Promoter Region of IL-18 in
Cal33 HNSCC Cells

As previously described, HPV E7 has been shown to be involved in alteration to gene
expression through interactions with gene promoters (Chalerpet K. et al. 2015, Cicchini L.
et al 2016, Cicchini L. et al 2017). To determine if HPV E7 affects the IL-18 promoter, I
PCR amplified 1.5kb of the IL18 genes promoter region from human genomic DNA and
cloned it into the pGL3-Basic luciferase expression vector. This region was selected as it
contains the IL18 gene’s promoter and sequences that demonstrated significantly more
DNA methylation in the TCGA HPV+ samples when compared to HPV- samples and
normal adjacent tissues (Figure 3.4 C-F). This region has also previously been shown to
function as an active promoter in luciferase assays by another group (Kalina U. et al 2000).
To test the efficacy of this newly cloned vector, both pGL3-Basic and IL-18-PromoterpGL3-Basic were transfected into Cal33 HNSCC cell lines, and after transfection the cell
lysate was subjected to a luciferase assay. Cal33 cells were chosen because they are HPVHNSCC cells that express a relatively high level of endogenous IL-18. This assay
confirmed the newly constructed IL-18 reporter displayed significantly greater expression
than the parent vector lacking the IL-18 promoter (Figure 3.7). This vector was then
subsequently co-transfected with a mammalian expression vector expressing HPV-16 E7
fused with zsGreen fluorescent protein via a T2A self-cleavage site. This allowed me to
confirm transfection efficiency and test the function the of HPV-16 E7 protein without
potential confounding effects related to fusion to a large fluorescent protein tag. These
experiments showed a significant decrease in the expression of luciferase by the IL-18
promoter when it was co-expressed with HPV-16 E7 (Figure 3.8A). I also tested the ability
of HPV-16 E7 to impact the IL-18 promoter when tagged with both EGFP and myc tags at
the N-terminus. Cal33 HNSCC cells co-transfected with the pCANmycEGFP-HPV16-E7
construct and IL-18 promoter luciferase vector similarly exhibited a reduction in luciferase
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expression (Figure 3.8 B). Expression of HPV-16 E7 zsGreen vector was confirmed by
western blots (Figure 3.9 A/B).

3.3.2

Mapping the Regions of HPV-16 E7 Involved in Repressing
Transcription from the IL-18 Promoter in Cal33 HNSCC Cells

I next tested a series of HPV-16 E7 fragments for their ability to repress luciferase
expression from the IL-18 reporter vector. I initially focused on the conserved regions of
E7, which are referred to as conserved region 1 (CR1; spanning amino acids 1-15),
conserved region 2 (CR2; spanning amino acids 16-28), and conserved region 3 (CR3;
spanning amino acids 39-98). These regions were selected to determine which conserved
region of E7 was responsible for suppression of the IL-18 promoter. The two fragments of
the HPV E7 CR3 were also selected, spanning amino acids 39-58 and amino acids 59-98,
as HPV E7 has been described to interact with DNMT1 through CR3 and this interaction
could play are role in repression. I co-transfected Cal33 cells with the IL-18 luciferase
reporter and either empty vector or the pCANmyc-EGFP constructs expressing the
different conserved regions of HPV-16 E7. I observed a significant reduction in the
expression of luciferase by the vector expressing the first 19aa of CR3 (pCAN-myc-EGFPE7aa39-58) when compared to the transfected empty vector, while the other portions of
HPV-16 E7 had no significant effect of the expression of luciferase, except for full length
HPV-16 E7 (Figure 3.10).

3.3.3

Testing the Effects of Various HPV E7s on Transcription
from the Promoter Region of IL-18 in HNSCC Cal33 Cells

I next examined a panel of different high and low-risk HPV E7 proteins on the expression
of the IL-18 reporter in Cal33 HNSCC cells. This panel of 11 HPV E7 genes were
expressed from the same pCANmyc-EGFP mammalian expression construct used for
HPV-16 E7. I observed near universal suppression of luciferase expression by the E7
proteins of all HPV types, with the noticeable exception of HPV-31 E7 (Figure 3.11). Thus,
most, but not all HPV types appear capable of repressing transcription from the IL-18
promoter.
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Figure 3.7: A 1.5kBp fragment of the IL-18 promoter is sufficient to drive
expression of luciferase transcription when transfected into Cal33 HNSCC cells.
Transfections of Cal33 cells were done using Lipofectamine 3000. When compared to the
transfection of a promoter-less pGL3-Basic reporter construct, there was a significant
increase in the production of luciferase by the vector containing a 1.5kb fragment of the
IL-18 promoter. Statistical analysis was conducted through a parametric t-test
(p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns)
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Figure 3.8: Expression of luciferase by the IL-18 reporter is repressed by cotransfection with HPV-16 E7 constructs.
Co-transfections of Cal33 cells were done using lipofectamine 3000 transfection reagent.
There was significantly less luciferase expression when the construct was co-transfected
with either (A) zsGreen HPV-16 E7 expression vector or (B) the pCANmyc-EGFP HPV16 E7 vector. Statistical analysis was conducted through a parametric t-test
(p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns)
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Figure 3.9: Expression of HPV-16 E7 by zsGreen
A western blot was performed using cellular lysate from Cal33 cells transfected with the
empty vector zsGreen vector, a transfection control EGFP expressing vector or our
zsGreen-HPV-16 E7 mammalian expression vector. (A) The blot was probed using antiE7 antibody and the arrow indicates the band with the size expected for E7 with an
additional blot of the cell lysate for our (B) loading control of ɑ-tubulin.
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Figure 3.10: Mapping the region of HPV-16 E7 required for repressing expression of
the IL-18 promoter luciferase construct luciferase.
Cal33 HNSCC cells were co-transfected with the IL-18 luciferase reporter and vectors
expressing the indicated portions of HPV-16 E7 denoted by the amino acids (aa) present.
There was significantly less expression of luciferase when the construct was co-transfected
with full length E7 or the fragment corresponding to aa39-98. Statistical analysis was
conducted through a parametric t-test (p<0.0001=****, p<0.001=***, p<0.05=*,
p>0.05=ns).
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Figure 3.11: The E7 proteins from most HPV types repress expression from the IL18 luciferase reporter.
Cal33 HNSCC cells were co-transfected with the IL-18 luciferase reporter and vectors
expressing the E7 proteins of the indicated HPV types. The E7 proteins from all HPV types
except HPV-31 repressed IL-18 expression. Statistical analysis was conducted through a
parametric t-test (p<0.0001=****, p<0.001=***, p<0.05=*, p>0.05=ns).
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Chapter 4

4

Discussion

4.1 General Discussion
4.1.1

The Suppression of the IL-18 Pathway is a Common
Element Across HPV+ Head and Neck Cancers in the TCGA
Head and Neck Cohort

HPV is a human tumor virus that is responsible for a significant fraction of human cancers
(Bansal A. et al 2016). In addition to altering host cell growth, we hypothesized that the
ability of HPV to suppress local immune responses could contribute to immune evasion
and chronic infection. The work presented in this thesis examines the effects of HPV on
the immune system, with a specific emphasis on IL-18. IL-18 is a constitutively expressed
proinflammatory cytokine in the epithelium (Sugawara S. et al 2001). This cytokine is an
important component of the barrier function of the mucosa tissues typically infected by
HPV. IL-18 has a wide variety of antiviral and anticancer effects in the body through its
stimulatory effects on NK cells and T-cells, which leads to the subsequent production of
IFNγ. In the context of HPV infections, avoiding these cytotoxic immune cells and
apoptosis of infected or oncogenically transformed host cells is important for persistence
of viral infection and tumour survival. We hypothesized that the HPV oncogenes
expression in HPV-dependent head and neck cancers suppresses the IL-18
proinflammatory pathway, contributing to oncogenesis.
Through analysis of the data from the TCGA, I observed a clear reduction in the level of
IL18 mRNA in HPV+ head and neck cancers compared to their HPV- counterparts and
normal non-cancerous adjacent tissues. IL18 appeared to be specifically targeted, as
expression of the other IL-1 superfamily cytokines were not reduced in HPV+ cancers
when compared to HPV- cancers and normal adjacent tissues. Likely, IL-18 is the largest
barrier to HPV during the infection of the epithelium, as it is the only cytokine within this
family that is constitutively produced within these tissues (Lopez-Castejon G. and Brough
D. 2017, Seidelin J. B. et al 2009). Although constitutively expressed, Il-18 expression is
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further elevated in epithelial cells in direct response to the detection of dsDNA outside of
the cell nucleus through the AIM2 inflammasome (Yogarajah T. et al 2017).
In addition to IL-18 itself, I extended my studies to examine the impact of HPV on the
expression of other components of the IL-18 pathway using gene expression data from the
TCGA head and neck cohort. In agreement with the findings of the MacDonald lab
(Richard K. H. et al 2014), I found that IL18BP mRNA expression was elevated in HPV+
cancers when compared to HPV- cancers and normal non-cancerous tissues. Expression of
CASP1, which cleaves and activates pro-IL-18, was also found to be reduced in HPV+
cancers when compared to HPV- cancer and normal adjacent tissues. Interestingly, CASP1
mRNA expression appears to be elevated in HPV- cancers when compared to normal
adjacent tissues, accentuating the difference between HPV+ and HPV- HNSCC. PYCARD,
which encodes ASC, a key component of the inflammasomes that activates caspase-1, is
similarly reduced in HPV+ cancers when compared to HPV- cancers. Taken together, these
results suggest HPV exerts a concerted antagonistic effort on expression of the components
of the IL-18 inflammatory pathway in head and neck cancers, which may contribute to this
disease.
HPV-16 is the most frequent HPV associated with HNSCC (Kobayashi K. et al 2018).
However, infection with other high-risk HPVs like HPV-33 can also lead to these cancers,
and these exhibit a poorer prognosis in comparison to HPV16+ HNSCC (Chatfield-Reed
K. et al 2020, Bratman S. V. et al 2016). A comparison of the relative IL18 mRNA
expression levels across patient samples did not identify any significant difference between
HPV-16+ cancers or those caused by other HPV types. This suggests that all HPVs can
reduce IL18 mRNA expression and that the relative activity of this pathway does not
contribute to the observed differences in patient prognosis between these two groups of
HPV+ HNSCC.

4.1.2

IL-18 and IL-18BP Expression is also Altered in HPV+
HNSCC Cell Lines

After our examination of the expression of IL-18 pathway components in primary head and
neck cancer tissues from the TCGA, we examined cultured HNSCC cell lines to see if they
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similarly exhibit the same HPV dependent IL-18 repression and IL-18BP upregulation. Not
only was I looking for a replication of the TCGA findings, I was also hoping to determine
if HNSCC cell lines could serve as potential working models for studying the mechanism
by which HPV affects the IL-18 pathway in terms of experimentation and laboratory
manipulation. I examined a panel of HPV+ and HPV- HNSCC-derived cell lines for
mRNA expression levels of IL-18 pathway components by qPCR, as well as internal and
secreted protein levels by western blot and ELISA, respectively. My findings in these cell
lines reflected the findings of the TCGA. Specifically, there was a significant reduction in
IL18 mRNA and IL-18 protein in HPV+ cell cultures compared to HPV- cell cultures. In
addition, the expression of IL18BP mRNA was significantly increased in HPV+ cell lines
when compared to HPV- cell lines. However, I was unable to detect IL-18BP protein
intracellularly or within the media from cultured cells. My observation that the IL-18
pathway is similarly repressed in HPV+ HNSCC cell lines compared to HPV- lines
suggested that the continued expression of HPV oncogenes in these cells is likely consistent
or correlates with these effects. These results also suggest that experimental manipulation
of HPV- HNSCC cell lines may allow us to investigate the mechanism by with HPV affects
this pathway.

4.1.3

HPV Suppression of IL18 mRNA Expression may be an
Epigenetic Effect Mediated by Changes in Promoter
Methylation.

IL-18 is constitutively expressed in the epithelium (Sugawara S. et al 2001). Actively
expressed genes generally exhibit reduced promoter methylation. Importantly, HPV E7 has
been shown to repress transcription by other genes by binding and activating DNMT1, a
methyltransferase that induces the methylation of CpG sites in genomic DNA (Burgers W.
A. 2007). I next determined if HPV was affecting methylation of the IL18 locus in head
and neck cancers using the genome wide methylation data from the TCGA. We looked at
data from 24 DNA methylation probes surrounding the IL18 gene. I found a pattern of
significantly elevated DNA methylation in HPV+ cancers throughout the IL18 gene
promoter. These data suggest that increased methylation of the IL18 promoter by HPV is
at least in part responsible for the decreased level of IL18 mRNA observed in HPV+
HNSCC. Interestingly, HPV+ precancerous lesions and cancers of the cervix develop
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distinct patterns of DNA methylation, and this is considered a hallmark of these virallyderived cancers (Verlaat W. et al. 2018, Widschendter A. et al. 2004) that may similarly
extend to HPV+ HNSCC.

4.1.4

HPV E7 is Sufficient to Repress Transcription from the IL18
Promoter in Cell Culture Models

HPV-dependent head and neck cancers consistently retain expression of both the E6 and
E7 oncogenes (Yeo-The N. S. L. et al 2018). Given the increases in IL18 promoter
methylation identified using the TCGA data, and the known interaction of HPV-16 E7 with
DNMT1 and histone deacetylase 1 (HDAC1), we next tested whether HPV E7 was
sufficient to repress transcription from the IL18 promoter using luciferase reporter assays.
We used a luciferase reporter containing a 1500bp of the IL18 promoter that had previously
been shown to be sufficient to direct transcription from the IL18 gene (Kalina U. et al 2000)
and also contains the CpG sequences exhibiting the largest changes of methylation between
HPV+ and HPV- head and neck cancers. We selected the Cal33 cell line for these
experiments, as they are HPV-, express high levels of endogenous IL-18 and are relatively
easy to transfect with plasmid DNA. In these experiments, expression of HPV-16 E7
significantly decreased the activity of the IL18 promoter when compared to our control
vectors that did not express E7. This result shows that HPV-16 E7 can suppress
transcription from the IL18 promoter in HPV- cell lines and that this functions via elements
contained within the 1500bp located upstream of the IL18 transcription start site.
Further luciferase assays with vectors expressing isolated conserved regions of HPV-16 E7
mapped the repression function of E7 to a subregion of CR3 spanning residues 39-58. CR3
is responsible for the ability of HPV to bind several proteins involved in gene expression,
like DNMT1 and HDAC1, which function by methylating CpG sites, deacetylation of
histones, and altered chromatin structure (Delcuve G. P. et al 2012, Damelin M. and Bestor
T. H. 2007). Although not precisely defined, the interactions of these epigenetic regulators
with E7 is usually attributed to the zinc binding domain found near the end of CR3 (Brehm
A. et al 1999, Longworth M. S. and Laimins L. A. 2004). However, Ski interacting protein
(SKIP), a transcriptional co-regulator that aids in overcoming the pRb-mediated cell cycle
checkpoints, is known to interact with the 19 amino acids at the beginning of CR3 of
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HPV16 E7 (Prathapam T. et al 2001). Future investigations into a potential role for SKIP
in IL18 dysregulation by HPV should be a high priority.
I also tested a panel of high and low risk HPV E7’s for repression of transcription from the
IL18 promoter, and this showed that all the different HPV E7’s were able to suppress
luciferase activity, with the exception of HPV31 E7. This is also consistent with the data
from the TCGA, which showed that head and neck cancers caused by other HPV types
besides HPV-16+ cancers expressed similarly reduced levels of IL18 mRNA. Thus,
repression of IL18 transcription seems to be a highly conserved function across most HPV
types, whether high or low risk. Although suppression of the IL-18 pathway may contribute
to cancer formation, it is clearly not sufficient, as low risk HPVs also possess this activity.

4.2

Conclusion

The goal of this thesis was to examine the effect of HPV on the IL-18 pathway in head and
neck cancers. My investigations using TCGA data from primary human tumors, cultured
HNSCC cells, and the IL-18 promoter all indicate that there is a concerted effort by HPV
to suppress the activity of IL-18 through the repression of its expression, repression of its
activators, and increased expression of IL-18BP, a negative regulator of IL-18.
Furthermore, our results indicate that suppression of IL-18 is mediated via the CR3 region
of E7 and is a conserved function of both high and low-risk E7. A summation of the effect
of HPV on the IL-18 pathway is presented in Figure 4.1A.
My studies identified additional avenues by which HPV can maintain an anti-inflammatory
environment to sustain persistent infections that can evade the immune system for months
to years within their hosts. Specifically, I have found that HPV can suppress the activity of
the proinflammatory IL-18 pathway, which is vital in epithelial defense. This expands our
understanding beyond the already known ability of the HPV E6 and E7 oncogenes to
increase the expression of IL-18BP (Richards K. H. et al 2014). Indeed, our results suggest
that the pervasiveness of IL-18 suppression extends far further, to include the effects on
expression of inflammasome components and IL-18 itself. The concerted downregulation
of IL-18 activators and IL-18 itself confirms the importance of the IL-18 pathway in
epithelial barrier function. It further emphasizes how important the reduction of the activity
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A

B

Figure 4.1: A model of the effect of HPV on the IL-18 proinflammatory pathway.
(A) A model of the regulation imposed by HPV on the IL-18 pathway through the
repression of IL-18’s activator caspase-1 and IL-18 itself, and the upregulation of IL-18BP.
(B) Points of intervention that could potentially restore immune cell activation dependent
on IL-18’s antiviral and anticancer activity
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of this cytokine is for the HPV replication cycle as well as the oncogenesis of HPV
dependent head and neck cancer.
In addition to a further understanding of HPV’s interactions with the host immune system,
this work suggests that the loss of the IL-18 proinflammatory response could contribute to
the virus’s ability to induce cancer. The loss of the IL-18 immune response means a loss
of the cells ability to activate immune cells in response to the detection of dsDNA in the
cytoplasm, a likely indication of HPV infection. As discussed earlier in this thesis, HPV+
cancers are mostly derived from chronic infections with high-risk HPV. These long-term
persistent infections are likely aided by the loss immune of cell stimulation. IL-18mediated activation of NK cells and cytotoxic T-cells not only functions to enhance the
destruction of infected cells, but to also destroy cells undergoing uncontrolled replication
and showing signs of cellular stress (Yasuda K. et al 2019). The loss of these activities
could protect HPV infected cells from clearance by the immune system, by contributing to
the formation of an anti-inflammatory haven for these precancerous lesions to develop and
progress to malignancy.
My studies may have additional impact beyond an enhanced understanding of the biology
of HPV infection. Importantly, my work raises the possibility that the restoration of the IL18 response in these HPV+ cancers could potentiate the benefits of traditional cancer
treatments and immunotherapies. Recombinant IL-18 has been purified, is commercially
available, and can potentially act to stimulate other immunotherapies in the reactivation of
cytotoxic immune cells (Robertson M. J. et al 2006, Senju H. et al 2018, Zhou T et al
2020). For example, IL-18 has been shown to have several protective and stimulatory
effects when used in mouse models of gastrointestinal cancer models (Sussman D. A. et al
2012, Salcedo R. et al 2010), lymphoma models (Ni J. et al 2012, Srivastava S. et al 2013),
melanoma models (Nagai H. et al 2002, Cho D. et al 2000), and bacterially induced cancer
models. These studies show that increased activity in NK cells resulted in reduced
tumorigenesis, inhibited tumour growth, and protected against metastatic cancer spread,
suggesting that IL-18 could enhance immunotherapy (Srivastava S. et al 2010).
Alternatively, to combat the HPV-induced overexpression of IL-18’s suppressor IL-18BP,
the introduction of an antibody-based therapeutic that blocks IL-18BP’s binding site could
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also allow reactivation of endogenous IL-18 signaling by blocking the sequestration of the
IL-18 cytokine (Figure 4.1 B). This would likely have to be used sparingly and in careful
dosages, as a chronic overabundance of IL-18 has been associated with inflammatory skin
diseases like systemic lupus erythematosus and psoriasis, as well as bowel disease like
irritable bowel syndrome (IBS) and Crohn’s disease (Kanai T. et al 2001, Favilli F. et al
2009, Lee J. H. et al 2015).

4.3

Future Directions and Experiments

Studies of the effect of HPV on the activity of IL-18 is far from over, and there are several
additional experiments that would benefit our understanding of their interactions. This
includes using an existing series of point mutants within HPV-16 E7 to identify the exact
residues of E7 necessary for repressing transcription from the promoter, examining the
ability of non-oncogenic E7s to repress the IL-18 promoter, examining the differences
between HPV-16 and HPV-31 E7, and further experimental analysis to try to measure the
impact of HPV of the expression of IL-18BP protein. Each of these is briefly described
below.
A previous PhD student within the Mymryk lab, Dr. Biljana Todorovic, developed an
extensive series of point-mutants within HPV-16’s E7, all cloned within the same
mycEGFP mammalian expression vector used in my studies (Todorovic B. et al 2012).
Luciferase assays using these point mutants within CR3 could identify which amino acids
are important to the suppression of the IL-18 promoter. Coimmunoprecipitations assays
with HDAC1, DMNT1, and SKIP would confirm that wild-type HPV-16 E7 is indeed
binding to these transcriptional modulators, and if binding depends on the same regions
required for repression of transcription.
Additionally, a comparative analysis of the E7 proteins from HPV-16, HPV-31, and nononcogenic HPVs, like the Beta-HPV E7s, could help illuminate the mechanisms in which
HPV mediates the oncogenesis of their host cells. Examining the non-oncogenic E7’s
through another series of luciferase experiments could help to understand if the suppression
of IL-18 is a function conserved only among cancer causing HPV, or if it is a common
activity among most HPVs. Additionally, as HPV-31 did not repress the IL-18 luciferase
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vector, I would first like to confirm the expression of E7 from HPV-31 within these cells,
as lack of activity could simply reflect a lack of expression. Should the presence of HPV31 E7 be confirmed, a comparative analysis of the amino acids sequences that differ
between HPV-31 and HPV-16 E7 proteins could help identify the important motifs
necessary for repression of expression and confirm our point mutation data.
Further experimentation using our cultured cell lines would extend our understanding of
the mechanistic basis by which E7 represses IL-18 expression. One such experiment would
be through the stable lentivirus-mediated transduction of HPV-16 E7, selected E7 point
mutants lacking activity, or an empty control vector into our HPV- cell lines. We would
then be able to examine the effects of E7 in a context that more closely resembles a longterm HPV infection. Here, we could conduct an analysis of the endogenous changes in IL18BP mRNA, promoter methylation, histone acetylation, and IL-18’s protein and mRNA
through qPCR, methylation analysis, western blots, and ELISAs. The examination of such
an engineered cell line through qPCR and western blots could be expanded to include
studies of the effect of E7 on the other modulated proteins we identified using the TCGA
data, including caspase-1, This would lead to a more comprehensive understanding of the
effect of HPV on their expression. This would also provide a more realistic model
examining the effect of E7 on histone acetylation and DNA methylation, as they would be
interacting with chromosomal DNA instead of transiently transfected promoter templates
within a circular plasmid. As E7 interacts with both HDAC1 and DNMT1, they may both
functions to exhibit synergistic effects in IL-18 downregulation.
Additionally, as I was unable to detect IL-18BP production by the HNSCC cell lines or
induce its expression with IFNγ, I would like to conduct further studies using an in vitro
model in which IL-18BP can be examined. The MacDonald laboratory (Richards K. H. et
al 2014) previously reported that they were able to induce the production of IL-18BP with
IFNγ within cell cultures of primary foreskin keratinocytes. Future experiments
introducing E7 into primary keratinocytes could be more relevant than culture models
using tumor cell derived lines for these studies as the activity of E7.
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In summation, IL-18 is an important component of barrier maintenance within the
epithelium, acting as a first responder cytokine in the activation of both the innate and
adaptive immune system. To avoid this response, HPV employs several mechanisms to
downregulate this inflammatory pathway. This includes downregulating the expression of
IL18, the downregulation of its activators CASP1 and AIM2, and the upregulation of the
negative regulator IL18BP. The downregulation of IL-18 can be attributed to the activity
of the HPV oncoprotein E7, specifically via CR3. HPV mediated downregulation of IL-18
transcription is mediated through the first 1.5kbp of the IL18 promoter. This biological
phenomenon warrants further experimental exploration, including the mechanistic studies
related to E7 interactions with this promoter, transcriptional regulatory factors, and the
important motifs within E7 that mediate this binding. It will also be important to examine
this loss of proinflammatory cytokines activity in tumor models, as the downregulation of
IL-18 results not only in the loss of its antiviral properties, but also downregulates its anticancer properties, which could contribute to the formation and maintenance of an antiinflammatory environment that allows for HPV infected cells to progress to cancer.
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Appendices

Appendix A. Standard curves of GAPDH, IL-18, and IL-18BP used for the
calculation of mRNA counts.
I used plasmid DNA containing the transcribed sequences of (A) GAPDH, (B) IL-18, and
(C) IL-18BP within. qPCR of a serial dilution of these plasmids allowed us to develop
standard curves in which were utilized in mRNA calculations. To assure proper equation
of the line is developed, correlation value of R2>0.95, and an efficiency of 100%+/-10%
must be achieved.
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GAPDH

CT-Value

A

0.01

0.1

1

10

100

Plasmid DNA (ng)
Slope: -3.286, Y-intercept: 14.623, R2: 0.984, Efficiency: 101.53%

IL-18

CT-Value

B

0.01

0.1

1

10

Plasmid DNA (ng)
Slope: -3.109, Y-intercept: 14.981, R2: 0.986, Efficiency: 109.728%

100
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IL-18BP

CT-Value

C

0.01

0.1
1
Plasmid DNA (ng)

10

Slope: -3.531, Y-intercept: 19.05, R2: 0.992, Efficiency: 91.972%
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